DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS
The present invention relates to methods, devices, instruments, processes, and systems for the highly specific, targeted molecular analysis of regions of human genomes and transcriptomes from the blood, i.e. from cell free circulating DNA, exosomes, microRNA, lncRNA, circulating tumor cells, or total blood cells. The technology enables highly sensitive identification and enumeration of mutation, expression, copy number, translocation, alternative splicing, and methylation changes using spatial multiplexing and combined nuclease, ligation, polymerase, and sequencing reactions. Such technology may be used for non-invasive early detection of cancer, non-invasive cancer prognosis, and monitoring both treatment efficacy and disease recurrence of cancer.
This application claims the priority benefit of U.S. Provisional Patent Application Ser. No. 62/478,412, filed Mar. 29, 2017, which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTIONThe present invention relates to devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligation, polymerase, and sequencing reactions.
BACKGROUND OF THE INVENTIONAdvances in DNA sequencing hold the promise to standardize and develop non-invasive molecular diagnosis to improve prenatal care, transplantation efficacy, cancer and other disease detection and individualized treatment. Currently, patients with predisposing or early disease are not identified, and those with disease are not given the best treatment—all because of failures at the diagnostic level.
In the cancer field, there is a need to develop such technology for early detection, guiding therapy, and monitoring for recurrence—all from a blood sample. This includes the need to develop: (i) high sensitivity detection of single base mutation, small insertion, and small deletion mutations in known genes (when present at 1% to 0.01% of cell-free DNA); (ii) high sensitivity detection of promoter hypermethylation and hypomethylation (when present at 1% to 0.01% of cell-free DNA); (iii) accurate quantification of tumor-specific mRNA, lncRNA, and miRNA isolated from tumor-derived exosomes or RISC complex, or circulating tumor cells in blood; (iv) accurate quantification of tumor-specific copy changes in DNA isolated from circulating tumor cells; (v) accurate quantification of mutations, promoter hypermethylation and hypomethylation in DNA isolated from circulating tumor cells. All these (except quantification of tumor-specific copy changes in DNA isolated from circulating tumor cells) require focusing the sequencing on targeted genes or regions of the genome. Further, determination of the sequence information or methylation status from both strands of the original fragment provides critically needed confirmation of rare events.
Normal plasma contains nucleic acids released from normal cells undergoing normal physiological processes (i.e. exosomes, apoptosis). There may be additional release of nucleic acids under conditions of stress, inflammation, infection, or injury. In general, DNA released from apoptotic cells is an average of 160 bp in length, while DNA from fetal cells is an average of about 140 bp. Plasma from a cancer patient contains nucleic acids released from cancer cells undergoing abnormal physiological processes, as well as within circulating tumor cells (CTCs). Likewise, plasma from a pregnant woman contains nucleic acids released from fetal cells.
There are several challenges for developing reliable diagnostic and screening tests. The first challenge is to distinguish those markers emanating from the tumor or fetus that are indicative of disease (i.e. early cancer) vs. presence of the same markers emanating from normal tissue. There is also a need to balance the number of markers examined and the cost of the test, with the specificity and sensitivity of the assay. This is a challenge that needs to address the biological variation in diseases such as cancer. In many cases the assay should serve as a screening tool, requiring the availability of secondary diagnostic follow-up (i.e. colonoscopy, amniocentesis). Compounding the biological problem is the need to reliably detect nucleic acid sequence mutation or promoter methylation differences, or reliably quantify DNA or RNA copy number from either a very small number of initial cells (i.e. from CTCs), or when the cancer or fetus-specific signal is in the presence of a far larger amount of nucleic acid emanating from normal cells. Finally, there is the technical challenge to distinguish true signal resulting from detecting the desired disease-specific nucleic acid differences vs. false signal generated from normal nucleic acids present in the sample vs. false signal generated in the absence of the disease-specific nucleic acid differences.
By way of an example, consider the challenge of detecting, in plasma, the presence of circulating tumor DNA harboring a mutation in the p53 gene or a methylated promoter region. Such a sample will contain a far larger amount of cell-free DNA arising from normal cells, where the tumor DNA may only comprise 0.01% of the total cell-free DNA. Thus, in attempting to find the presence of such mutant DNA by total sequencing, one would need to sequence 100,000 genomes to identify 10 genomes harboring the mutations. This would require sequencing 300,000 GB of DNA, a task beyond the reach of current sequencing technology, not to mention the enormous data-management issues. To circumvent this problem, many groups have attempted to capture specific target regions or to PCR amplify the regions in question. Sequence capture has suffered from dropout, such that maybe 90-95% of the desired sequences are captured, but desired fragments are missing. Alternatively, PCR amplification provides the risk of introducing a rare error that is indistinguishable from a true mutation. Further, PCR loses methylation information. While bisulfate treatment has been traditionally used to determine the presence of promoter methylation, it is also destructive of the DNA sample and lacks the ability to identify multiple methylation changes in cell-free DNA.
There are several different approaches for reducing error rate and improving the accuracy of sequencing runs. A consensus accuracy may be achieved in the presence of high error rates by sequencing the same region of DNA 30 to 100 times. However, a high error rate makes it extremely difficult to identify a sequence variant in low abundance, for example when trying to identify a cancer mutation in the presence of normal DNA. Therefore, a low error rate is required to detect a mutation in relatively low abundance. The first approach termed tagged-amplicon deep sequencing (TAm-Seq) method (Forshew et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” Sci Transl Med. 4(136):136 (2012)) is based on designing primers to amplify 5995 bases that cover select regions of cancer-related genes, including TP53, EGFR, BRAF, and KRAS. This approach is able identify mutations in the p53 gene at frequencies of 2% to 65%. In this approach, primers are designed to pre-amplify the DNA (for 15 cycles) in a multiplexed reaction with many PCR primers. This creates both desired and undesired products, so it is followed with single-plex PCR to further amplify each of the desired products. The fragments are subjected to a final barcoding PCR step prior to standard next-generation sequencing. The advantage of this approach is it uses the time tested multiplexed PCR-PCR, which is unparalleled for amplification of low numbers of starting nucleic acids. The disadvantage is that this approach is unable to distinguish a true mutation from a PCR error in the early rounds of amplification. Thus, while the sensitivity of 2% (i.e. detecting one mutant allele in 50 wt alleles) is sufficient for evaluating late-stage cancers prior to making a treatment decision, it is not sensitive enough for early detection.
A variation of the first approach is termed Safe-Sequencing System “Safe-SeqS” (Kinde et al., “Detection and Quantification of Rare Mutations with Massively Parallel Sequencing,” Proc Natl Acad Sci USA 108(23):9530-5 (2011)), where randomly sheared genomic DNA is appended onto the ends of linkers ligated to genomic DNA. The approach demonstrated that the most mutations described from genomic sequencing are actually errors, and reduced presumptive sequencing errors by at least 70-fold. Likewise, an approach called ultrasensitive deep sequencing (Narayan et al., “Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-suppressed Multiplexed Deep Sequencing,” Cancer Res. 72(14):3492-8 (2012)) appends bar codes onto primers for a nested PCR amplification. Presumably, a similar system of appending barcodes was developed to detect rare mutations and copy number variations that depends on bioinformatics tools (Talasaz, A.; Systems and Methods to Detect Rare Mutations and Copy Number Variation, US Patent Application Publication No. US 2014/0066317 A1). Paired-end reads are used to cover the region containing the presumptive mutation. This method was used to track known mutations in plasma of patients with late stage cancer. These approaches require many reads to establish consensus sequences. These methods require extending across the target DNA, and, thus, it would be impossible to distinguish true mutation, from polymerase generated error, especially when copying across a damaged base, such as deaminated cytosine. Finally, these methods do not provide information on methylation status of CpG sites within the fragment.
The second approach termed Duplex sequencing (Schmitt et al., “Detection of Ultra-Rare Mutations by Next-Generation Sequencing,” Proc Natl Acad Sci USA 109(36):14508-13 (2012)) is based on using duplex linkers containing 12 base randomized tags. By amplifying both top and bottom strands of input target DNA, a given fragment obtains a unique identifier (comprised of 12 bases on each end) such that it may be tracked via sequencing. Sequence reads sharing a unique set of tags are grouped into paired families with members having strand identifiers in either the top-strand or bottom-strand orientation. Each family pair reflects the amplification of one double-stranded DNA fragment. Mutations present in only one or a few family members represent sequencing mistakes or PCR-introduced errors occurring late in amplification. Mutations occurring in many or all members of one family in a pair arise from PCR errors during the first round of amplification such as might occur when copying across sites of mutagenic DNA damage. On the other hand, true mutations present on both strands of a DNA fragment appear in all members of a family pair. Whereas artifactual mutations may co-occur in a family pair with a true mutation, all except those arising during the first round of PCR amplification can be independently identified and discounted when producing an error-corrected single-strand consensus sequence. The sequences obtained from each of the two strands of an individual DNA duplex can then be compared to obtain the duplex consensus sequence, which eliminates remaining errors that occurred during the first round of PCR. The advantage of this approach is that it unambiguously distinguishes true mutations from PCR errors or from mutagenic DNA damage, and achieves an extraordinarily low error rate of 3.8×10−10. The disadvantage of this approach is that many fragments need to be sequenced to obtain at least five members of each strand in a family pair (i.e. minimum of 10 sequence reads per original fragment, but often requiring far more due to fluctuations). Further, the method has not been tested on cfDNA, which tend to be smaller than fragments generated from intact genomic DNA, and thus would require sequencing more fragments to cover all potential mutations. Finally, the method does not provide information on methylation status of CpG sites within the fragment.
The third approach, termed smMIP for Single Molecule Molecular Inversion Probes (Hiatt et al., “Single Molecule Molecular Inversion Probes for Targeted, High-Accuracy Detection of Low-Frequency Variation,” Genome Res. 23(5):843-54 (2013) combines single molecule tagging with multiplex capture to enable highly sensitive detection of low-frequency subclonal variation. The method claims an error rate of 2.6×10−5 in clinical specimens. The disadvantage of this approach is that many fragments need to be sequenced to obtain at least five members of each strand in a family pair (i.e. minimum of 10 sequence reads per original fragment, but often requiring far more due to fluctuations). Also, the method requires extending across the target DNA, and thus it would be impossible to distinguish true mutation, from polymerase-generated error, especially when copying across a damaged base, such as deaminated cytosine. Further, the method has not been tested on cfDNA, which tend to be smaller than fragments generated from intact genomic DNA, and thus would require sequencing more fragments to cover all potential mutations. Finally, the method does not provide information on methylation status of CpG sites within the fragment.
The fourth approach, termed circle sequencing (Lou et al., “High-throughput DNA Sequencing Errors are Reduced by Orders of Magnitude Using Circle Sequencing,” Proc Natl Acad Sci USA 110(49):19872-7 (2013); Acevedo et al., “Mutational and Fitness Landscapes of an RNA Virus Revealed Through Population Sequencing,” Nature 2014 505(7485):686-90 (2014); and Acevedo et al., “Library Preparation for Highly Accurate Population Sequencing of RNA Viruses,” Nat Protoc. 9(7):1760-9 (2014)) is based on shearing DNA or RNA to about 150 bases, denaturing to form single strands, circularizing those single strands, using random hexamer primers and phi29 DNA polymerase for rolling circle amplification (in the presence of Uracil-DNA glycosylase and Formamidopyrimidine-DNA glycosylase), re-shearing the products to about 500 bases, and then proceeding with standard next generation sequencing. The advantage of this approach is that the rolling circle amplification makes multiple tandem copies off the original target DNA, such that a polymerase error may appear in only one copy, but a true mutation appears in all copies. The read families average 3 copies in size, because the copies are physically linked to each other. The method also uses Uracil-DNA glycosylase and Formamidopyrimidine-DNA glycosylase to remove targets containing damaged bases, to eliminate such errors. The advantage of this technology is that it takes the sequencing error rate from a current level of about 0.1 to 1×10−2, to a rate as low as 7.6×10−6. The latter error rate is now sufficient to distinguish cancer mutations in plasma in the presence of 100 to 10,000-fold excess of wild-type DNA. A further advantage is that 2-3 copies of the same sequence are physically linked, allowing for verification of a true mutation from sequence data generated from a single fragment, as opposed to at least 10 fragments using the Duplex sequencing approach. However, the method does not provide the ability to determine copy number changes, nor provide information on methylation status of CpG sites within the fragment.
The fifth approach, developed by Complete Genomics (Drmanac et al., “Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoanays,” Science 327(5961):78-81 (2010)) is based on using ligation reads on nanoball arrays. About 400 nucleotides of genomic DNA are circularized with linkers, cleaved, recircularized with additional linkers, and ultimately recircularized to contain about four linkers. The DNA undergoes rolling circle amplification using phi 29 DNA Polymerase to generate nanoballs. These are then placed onto an array, and sequenced using a ligation-based approach. The salient point of this approach, of relevance herein, is that multiple tandem copies of the same sequence may be generated and subsequently sequenced off a single rolling circle amplification product. Since the same sequence is interrogated multiple times by either ligase or polymerase (by combining rolling circle with other sequencing by synthesis approaches), the error rate per base may be significantly reduced. As such, sequencing directly off a rolling circle product provides many of the same advantages of the circle sequencing approach described above.
The sixth approach, termed SMRT—single molecule real time—sequencing (Flusberg et al., “Direct Detection of DNA Methylation During Single-Molecule, Real-Time Sequencing,” Nat Methods 7(6):461-5 (2010)) is based on adding hairpin loops onto the ends of a DNA fragment, and allowing a DNA polymerase with strand-displacement activity to extend around the covalently closed loop, providing sequence information on the two complementary strands. Specifically, single molecules of polymerase catalyze the incorporation of fluorescently labeled nucleotides into complementary nucleic acid strands. The polymerase slows down or “stutters” when incorporating a nucleotide opposite a methylated base, and the resulting fluorescence pulses allow direct detection of modified nucleotides in the DNA template, including N6-methyladenine, 5-methylcytosine and 5-hydroxymethylcytosine. The accuracy of the approach has improved, especially as the polymerase may traverse around the closed loop several times, allowing for determination of a consensus sequence. Although the technique is designed to provide sequence information on “dumbbell” shaped substrates (containing mostly the two complementary sequences of a linear fragment of DNA), it may also be applied to single-stranded circular substrates.
Several research groups and companies have developed kits to amplify specific target sequences while appending a unique molecule identifier (UMI) or barcode to each fragment.
An elegant approach termed SiMSen-Seq (Simple, Multiplexed, PCR-based barcoding of DNA for Sensitive mutation detection using Sequencing) uses two round of PCR with high fidelity polymerase to append a hairpin-protected barcode to each fragment, as well as external universal primers (Ståhlberg et al., “Simple, Multiplexed, PCR-based Barcoding of DNA Enables Sensitive Mutation Detection in Liquid Biopsies Using Sequencing,” Nucleic Acids Res. 44(11):e105) (2016)). In this approach, one primer contains an adapter stem to “hide” the barcode from the target DNA, such that the primer hybridization to the target is not misdirected by random bases in the barcode sequence. The other primer is a regular primer with an Illumina adapter sequence on the end. After two rounds of amplification with a high-fidelity polymerase, adapter, and barcode are appended to target fragments. After protease treatment and dilution, a second PCR is performed using Illumina adapters containing patient identifier barcodes. The approach did identify hot spot positions for raw sequencing errors, and currently is designed to barcode only one strand.
In the ThruPLEX Tag-seq Kit (Rubicon Genomics), stem-loop adapters are ligated to the ends of double-stranded DNA. As with standard Y adapters, genomic DNA is repaired to yield blunt ends. In the next step, stem-loop adaptors containing unique molecular tags (UMI) with blocked 5′ ends are ligated to the 5′ end of the DNA, leaving a nick at the 3′ end of the target fragment. The stem-loop adaptors do not have single-strand overhangs preventing ligation to each other, both of which contribute to non-specific background found with many other NGS preparations. Instead, the stem-loop adapters contain a cleavable replication stop base. In the final step, the 3′ ends of the DNA are extended to complete library synthesis and Illumina-compatible indexes are added through a high-fidelity amplification. Any remaining free adaptors are degraded. Ligation reactions can be inefficient, which creates the potential of lower yields when mutational sample input is limited. Further, this approach does not select for specific targets.
In the NEBNext Direct target enrichment approach (New England Biolabs), DNA is fragmented to about 150-200 bp in length. The fragmented DNA is rapidly hybridized to biotinylated oligonucleotide “baits” that define the 3′ end of each target of interest. Such oligonucleotide baits are designed for both the top and bottom strands of each target. The bait-target hybrids are bound to streptavidin beads, and any 3′ off target sequence is trimmed enzymatically, to generate a blunt end. This combination of a short hybridization time with the enzymatic removal of 3′ off target sequence enables greater sequencing efficiency relative to conventional hybridization-based enrichment methods. The trimmed targets are then converted into Illumina-compatible libraries that include unique molecular identifiers (UMI) and a sample barcode. This conversion is accomplished as follows. The blunt end is dA-tailed with terminal transferase, allowing for ligation of a hairpinned loop sequence to the single-stranded dA overhang. Next, the probe is extended with a DNA polymerase to generate a copy of the original fragment and generate double-stranded DNA with random 5′ ends. These ends are blunted (with T4 polymerase or DNA polymerase 1), and the 5′ end either contained a phosphate from the original fragmentation, or a phosphate is added using T4 kinase. This new end is now suitable for ligating on an adapter to the original target strand comprising a UMI sequence. The adapter hairpin loop is then cleaved, thus creating a top strand comprising of a 5′ adapter sequence, an UMI sequence, a stretch of 5′ target sequence, the desired target region up to the 3′ end complementary to the bait, a polydA sequence, and then a 3′ adapter sequence. This top strand may then be melted off the streptavidin beads, purified, and then is suitable for amplification with Illumina or Ion Torrent adapters containing patient identifier barcodes. Sequence-ready libraries are generated within one day. The procedure is compatible with most automated liquid handling instruments. Although the technique is designed to be highly efficient in capturing just the desired fragments, it is also a lengthy, multi-step procedure, with the potential of lower yields when mutational sample input is limited.
In the QIAseq targeted RNA sequencing approach (Qiagen Inc.) unique identifiers are appended to RNA sequences, allowing for their precise enumeration. After purifying the RNA sample, reverse transcriptase is used to synthesize cDNA. A composite primer comprising of a first 5′ universal sequence, an internal 12-base molecular tag (i.e. a UMI) and a gene-specific 3′ portion is used to make an extension product off the cDNA. After extension, the reaction is cleaned up to remove unreacted primers. This is followed by a first stage PCR using a universal primer and a second gene-specific primer comprising a second 5′ universal sequence. According to the manufacturer, the first gene-specific primers and the second gene-specific primers “never see each other, thereby minimizing primer dimers.” After the first PCR, there is an additional reaction clean-up step. This is followed by a second-stage PCR, using the universal adapter sequences to append Illumina or Ion Torrent adapters containing patient identifier barcodes. Sequence-ready libraries are generated within 6 hours. Since each initial cDNA molecule has presumably been extended by a primer comprising an UMI, one can count how many original transcripts of each RNA molecule are present by matching transcript with unique UMI, and thus distinguish 5 replicates of 1 transcript from 5 unique transcripts of the same gene. The technique is designed to enumerate RNA fragments as in RNA-seq, but for very specific desired fragments. Although it may also be adapted to identify low-abundant mutations, the multi-wash procedure creates the potential of lower yields when mutational sample input is limited.
In the Oncomine Cell-Free DNA assays for liquid biopsy clinical research (ThermoFisher Scientific), a two-step PCR reaction is used to amplify target sequences directly from cfDNA. Both forward and reverse composite primers comprise a first/second 5′ universal sequence, an internal unique molecular tag (i.e. a UMI) and a gene-specific 3′ portion. After exactly two cycles of PCR two composite double-stranded products are formed. The first product comprises the top-strand primer extension product, the top-strand target sequence, and the complement of the bottom-strand primer including the second universal sequence; hybridized to the initial extension of the bottom-strand primer including the bottom-strand target sequence. The second product comprises the bottom-strand primer extension product, the bottom-strand target sequence, and the complement of the top-strand primer including the first universal sequence; hybridized to the initial extension of the top-strand primer including the top-strand target sequence. Thus, both a top and a bottom strand contain universal adapter sequences and unique UMI sequences arising from each initial target strand. The target amplicons are then captured on a solid support purified from the gene-specific primers. The products are released from the solid support and then are suitable a second-stage PCR, using the universal adapter sequences to append Ion Torrent adapters containing patient identifier barcodes. Sequence-ready libraries are generated within a few hours, and then may be combined for further template preparation using emulsion PCR on beads. This approach is very rapid and robust; however, it does require the extra step of physically removing initial gene-specific primers, as well as a cleanup/size selection after the second PCR step (presumably to eliminate primer dimers), and it is unclear if this procedure creates the potential of lower yields when mutational sample input is limited.
The present invention is directed at overcoming these and other deficiencies in the art.
SUMMARY OF THE INVENTIONOne aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. This system comprises an inlet port and a cartridge. The cartridge defines a space containing multiple primary reaction chambers fluidically coupled to the inlet port to receive material from the inlet port and produce primary reaction chamber products from the material. The space also contains a product capture housing enclosing a solid support with a plurality of separate columns of a plurality of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual hydrophilic micro-pores or micro-wells separated by hydrophobic surfaces where primary reaction products are further reacted to create array products. The array products are detected in the micro-pores or micro-wells, where one or more of the columns of separate product capture subunits receive material which has passed through one of the multiple primary reaction chambers.
Another aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. The system includes: an inlet port; an outlet port; and a cartridge comprising an array of micro-pores or micro-wells, with the cartridge fluidically coupling the inlet port and the outlet port. The cartridge defines a space containing multiple primary reaction chambers fluidically coupled to the inlet port to receive material from the inlet port and produce primary reaction chamber products from the material. The space also contains multiple secondary reaction chambers, one or more of which are fluidically coupled to one of the multiple primary reaction chambers to receive material from one of the multiple primary reaction chambers, and to produce secondary reaction chamber products. At least some of the multiple primary and secondary reaction chambers are configured to maintain a trough of liquid in the multiple primary and secondary reaction chambers to facilitate mixing of sample, reagents, and/or product reactants for generating subsequent reaction chamber or array products. The space also contains multiple mixing chambers each fluidically coupled to one of the multiple secondary reaction chambers to receive material from one of the multiple secondary reaction chambers and to discharge material to the product capture housing so that each column of separate product capture subunits is fluidically coupled to one of the one or more mixing chamber to receive material from one of the one or more mixing chambers. The space also contains a product capture housing enclosing a solid support with a plurality of separate columns of a plurality of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual hydrophilic micro-pores or micro-wells separated by hydrophobic surfaces where secondary reaction products are further reacted to create array products. The array products are detected in the micro-pores or micro-wells, where one or more of the columns of separate product capture subunits receive material which has passed through one of the multiple primary reaction chambers.
Another aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. The system includes: an inlet port; an outlet port; and a cartridge fluidically coupling the inlet port and the outlet port. The cartridge defines a space containing a product capture housing enclosing a solid support with a plurality of separate columns of product capture subunits. Each separate product capture subunit comprises an array of a plurality of individual hydrophilic micro-pores separated by hydrophobic surfaces each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end. The product capture housing comprises a plurality of fluid channels to permit material to pass from the inlet port through a column of the product capture subunits into contact with the array of micro-pores in those subunits, and to the outlet port, where the plurality of fluid channels are located above and below the solid support.
A further aspect of the present invention relates to a method for preparing a system for identifying a plurality of nucleic acid molecules in a sample. The method comprises providing the system of the present invention and applying universal tag or capture oligonucleotide primers or probes to the micro-pores or micro-wells of the product capture subunits on the solid support within the product capture housing. As a result, the universal tag or capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. Following filling of the one or more primary reaction chambers and/or the one or more secondary reaction chambers, (if present), the process comprises conducting the primary and/or secondary reactions in the system and detecting the presence of target nucleic acid molecules in the sample in the micro-wells or micro-pores based on carrying out the primary and/or secondary reactions.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. Following the carrying out the primary and/or secondary reactions, the products of such reactions are amplified in the micro-wells or micro-pores under conditions where a polymerase, exonuclease, endonuclease, or ribonuclease cleaves one or more probes comprising a quencher and fluorescent group in a target-specific manner, such that fluorescent groups are liberated to generate signal if the target nucleic acid molecules are present in the sample.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. The process comprises providing a sample containing a plurality of target nucleic acid molecules, and then contacting the sample with a set of primary oligonucleotide primers having a first portion complementary to a portion of the target nucleic acid molecules and a second portion and a polymerase to form a polymerase chain reaction mixture. This mixture is subjected to a polymerase chain reaction in the primary reaction chambers to produce a set of amplification products. The amplification products are passed to the product capture housing enclosing a solid support with a plurality of separate columns of a plurality of capture subunits with each separate product capture subunit comprising an array of a plurality of individual micro-pores containing immobilized captures probes complementary to the second portion. The target nucleic acid molecules are captured and copied onto the immobilized capture probes. The nucleotide sequence of the immobilized target nucleic acid molecules is obtained by carrying out sequencing reactions in the micro-pores.
The present invention also relates to a process for preparing a microtiter plate for identifying a plurality of nucleic acid molecules in a sample. This involves providing a microtiter plate with a plurality of separate rows and columns of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual hydrophilic micro-wells separated by hydrophobic surfaces. The micro-wells of the microtiter plate are filled with an aqueous liquid containing oligonucleotide primers and/or probes. The microtiter plate is centrifuged to spread the aqueous liquid to unfilled micro-wells in each separate product capture subunit in the microtiter plates. Centrifuging is then terminated to urge the aqueous liquid out of contact with the hydrophobic surfaces. The aqueous liquid is evaporated, and the micro-wells are dried so that the oligonucleotide primers are left in the micro-wells.
Another aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. This system comprises an inlet port; an outlet port; and a cartridge fluidically coupled to the inlet port and the outlet port. The cartridge defines a space containing a product capture housing enclosing a solid support with a plurality of separate columns of product capture subunits. Each separate product capture subunit comprises an array of a plurality of individual hydrophilic micro-pores separated by hydrophobic surfaces each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end. The product capture housing comprises a plurality of fluid channels to permit material to pass from the inlet port through a column of the product capture subunits into contact with the array of micro-pores in those subunits, and to the outlet port, wherein the plurality of fluid channels are located above and below the solid support.
The present invention provides a set of devices, chambers, and assays for determining the cause of disease directly from a blood sample. Nucleic acids are purified from the clinical sample, targeted regions are subjected to a series of amplification reactions, and targets are identified or enumerated using either real-time PCR or sequencing as a readout.
This invention aims to help address the major diagnostic clinical challenges facing the U.S. and the world. The largest unmet need is to detect cancer at the earliest stage. An accessible and accurate early detection test has the potential to save over 300,000 lives annually in the U.S. and over 4,000,000 lives globally; it can save $300 billion in annual healthcare costs in the U.S. alone. One potential solution to this challenge is to provide a process and system for assaying multiple DNA mutational and methylation changes simultaneously, at the single-molecule level of sensitivity, as described in the present application. The same assay may also be used to monitor “cancer marker load” in the blood, to monitor how effectively a given treatment is killing residual cancer cells after surgery. A related challenge is to monitor the patient for early recurrence of the cancer, at a time when alternative treatments may still be effective. The present invention provides the flexibility to track cancer markers using either Taqman™ assays, sequencing, or both.
Infectious disease testing is migrating from single pathogen detection to symptom-based, or blood-borne pathogen detection. The present invention has the potential to provide accurate viral or bacterial load values for hundreds of targets simultaneously, to guide physicians to make clinically actionable decisions. For example, a patient suffering from a respiratory illness may be simultaneously tested for: all strains of influenza and Parainfluenza viruses, Adenovirus, Coronavirus, Rhinovirus, Enterovirus, Respiratory Syncytial Virus, Mycobacterium tuberculosis, Streptococcus pneumoniae, Group A Strep, Mycoplasma pneumoniae, Haemophilus Influenzae, etc. For blood-borne pathogens, the present invention may be used to distinguish: Staphylococcus, MRSA, Streptococcus, Enterococcus (VRE), Listeria, Acinetobacter, Enterobacter, E. coli (including toxin producers), Klebsiella (including KPC's), Pseudomonas, Proteus, Candida, Cryptococcus, Neisseria, Haemophilus, etc. International travelers with symptoms of fever may be tested to distinguish Zika virus from viral hemorrhagic fevers (Dengue, Yellow Fever, West Nile, arenaviruses, filoviruses, bunyaviruses, and other flaviviruses) or other viruses (Influenza, RSV, SARS, Chikungunya, rubella, measles, parvovirus, enterovirus, adenovirus, and alphavirus infection), or parasitic causes (malaria) or bacterial causes (group A streptococcus, rickettsia, borrelia, leptospirosis).
Non-invasive Prenatal Testing is currently being used to distinguish chromosomal copy anomalies using either chromosomal fragment counting via direct sequencing, or ligation-based detection with array-based quantification. The present invention's ability to accurately identify and enumerate targets at the single-molecule level would provide an opportunity to provide highly accurate results at lower costs. As an example, the enabling of more complete blood-based testing for life-threatening autosomal and X-linked recessive Mendelian disorders: Trisomy 21, 18, 13, Turner Syndrome, Kleinfelder Syndrome (Chromosomal copy anomalies); Duchenne and Beckers Muscular dystrophies, Cystic Fibrosis, and other inherited diseases.
One aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. This system comprises an inlet port and a cartridge. The cartridge defines a space containing multiple primary reaction chambers fluidically coupled to the inlet port to receive material from the inlet port and produce primary reaction chamber products from the material. The space also contains a product capture housing enclosing a solid support with a plurality of separate columns of a plurality of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual hydrophilic micro-pores or micro-wells separated by hydrophobic surfaces where primary reaction products are further reacted to create array products. The array products are detected in the micro-pores or micro-wells, where one or more of the columns of separate product capture subunits receive material which has passed through one of the multiple primary reaction chambers.
In one embodiment, the system for identifying a plurality of nucleic acid molecules in a sample of the present invention further comprises an outlet for discharging material from the product capture housing.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, the space defined by the cartridge further contains one or more initial reaction chambers into which the inlet port discharges material and from which material is discharged into the multiple primary reaction chambers.
In yet another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, the space defined by the cartridge further contains multiple secondary reaction chambers, one or more of which are fluidically coupled to one of the multiple primary reaction chambers to receive material from one of the multiple primary reaction chambers. The space also contains multiple mixing chambers each fluidically coupled to one of the multiple secondary reactions chambers to receive material from one of the multiple secondary reaction chambers and to discharge material to the product capture housing so that each column of separate product capture subunits is fluidically coupled to one of the one or more mixing chambers to receive material from one of the one or more mixing chambers.
In accordance with this embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, at least some of the multiple primary and secondary reaction chambers are configured to maintain a trough of liquid in the multiple primary and secondary reaction chambers.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, where the space defined by the cartridge further contains multiple secondary reaction chambers and multiple mixing chambers, the multiple primary and/or secondary reaction chambers each have an internal baffle to maintain a trough of liquid in the multiple primary and secondary reaction chambers.
In yet another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, where the space defined by the cartridge further contains multiple secondary reaction chambers and multiple mixing chambers, the multiple primary and/or secondary reaction chambers each have one or more of internal baffles to maintain a plurality of troughs of liquid in the multiple primary and secondary reaction chambers.
In a further embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, where the space defined by the cartridge further contains multiple secondary reaction chambers and multiple mixing chambers, each of the mixing chambers includes a divider extending from proximate to where material enters the mixing chamber to proximate to where material leaves the mixing chambers.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, where the space defined by the cartridge further contains multiple secondary reaction chambers and multiple mixing chambers, each of the mixing chambers includes a first surface which is highly hydrophobic and a second surface spaced from, and less hydrophobic than, the first surface, where the first and second surfaces extend from proximate to where material enters the mixing chamber to proximate to where material leaves the mixing chambers.
In yet another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, where the space defined by the cartridge further contains multiple secondary reaction chambers and multiple mixing chambers, the primary reaction chambers and/or the secondary reaction chambers comprise an internal surface on to which oligonucleotide primers or probes can be spotted.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample according to the invention, the product capture subunits comprise an array of a plurality of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end.
This system may further comprise a mesh screen covering the second ends of the micro-pores in the product capture housing or a bead placed in the individual micro-pores.
In a further embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the invention, the product capture subunits comprise an array of a plurality of individual micro-wells each having an open end and a closed end.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, where the space defined by the cartridge further contains multiple secondary reaction chambers and multiple mixing chambers, the product capture housing comprises a plurality of fluid channels to permit material to pass from the multiple mixing chambers, through a column of the product capture subunits into contact with the array of micro-pores or micro-wells in those subunits.
The plurality of fluid channels may be located above and/or below the solid support.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, the system may further comprise one or more valves for selectively introducing or removing reagents or reactants into or out of the cartridge through the inlet.
In a further embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, the system further comprises one or more valves for selectively introducing or removing reagents or reactants into or out of the product capture housing through the outlet port and/or through a location in the product capture housing distal from the outlet port.
In yet another embodiment of the system for identifying a plurality of nucleic acid molecules in a sample of the present invention, the system further comprises one or more heating elements in the cartridge proximate to the primary reaction chamber and/or the product capture housing.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in sample of the present invention, when the space defined by the cartridge further contains one or more initial reaction chambers into which the inlet port discharges material and from which material is discharged into the multiple primary reaction chambers, the system may further comprise one or more heating elements in the cartridge proximate to the initial reaction chambers.
In another embodiment of the system for identifying a plurality of nucleic acid molecules in sample of the present invention, when the space defined by the cartridge further contains multiple secondary reaction chambers and multiple mixing chambers, the system may further comprise one or more heating elements in the cartridge proximate to one of the secondary reaction chamber and/or the one or more of the mixing chambers.
Another aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. The system includes: an inlet port; an outlet port; and a cartridge comprising an array of micro-pores or micro-wells, with the cartridge fluidically coupling the inlet port and the outlet port. The cartridge defines a space containing multiple primary reaction chambers fluidically coupled to the inlet port to receive material from the inlet port and produce primary reaction chamber products from the material. The space also contains multiple secondary reaction chambers, one or more of which are fluidically coupled to one of the multiple primary reaction chambers to receive material from one of the multiple primary reaction chambers, and to produce secondary reaction chamber products. At least some of the multiple primary and secondary reaction chambers are configured to maintain a trough of liquid in the multiple primary and secondary reaction chambers to facilitate mixing of sample, reagents, and/or product reactants for generating subsequent reaction chamber or array products. The space also contains multiple mixing chambers each fluidically coupled to one of the multiple secondary reaction chambers to receive material from one of the multiple secondary reaction chambers and to discharge material to the product capture housing so that each column of separate product capture subunits is fluidically coupled to one of the one or more mixing chamber to receive material from one of the one or more mixing chambers. The space also contains a product capture housing enclosing a solid support with a plurality of separate columns of a plurality of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual hydrophilic micro-pores or micro-wells separated by hydrophobic surfaces where secondary reaction products are further reacted to create array products. The array products are detected in the micro-pores or micro-wells, where one or more of the columns of separate product capture subunits receive material which has passed through one of the multiple primary reaction chambers.
Another aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. The system includes: an inlet port; a second inlet location; an outlet port; and a cartridge fluidically coupling the inlet port, the second inlet location, and the outlet port. The cartridge defines a space containing a product capture housing enclosing a solid support with a plurality of separate columns of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual micro-pores. The product capture housing comprises a plurality of fluid channels to permit material to pass from the inlet port and/or the second inlet location through a column of the product capture subunits into contact with the array of micro-pores in those subunits, and to the outlet port, where the plurality of fluid channels are located above and below the solid support. One or more valves are used to selectively introduce or remove reagents or reactants into or out of the product capture housing through the inlet port, the outlet port and/or through the second inlet location in the product capture housing distal from the outlet port.
A further aspect of the present invention relates to a method for preparing a system for identifying a plurality of nucleic acid molecules in a sample. The method comprises providing the system of the present invention and applying universal tag or capture oligonucleotide primers or probes to the micro-pores or micro-wells of the product capture subunits on the solid support within the product capture housing. As a result, the universal tag or capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells.
The method for preparing a system for identifying a plurality of nucleic acid molecules in a sample of the present invention may further involve filling the one or more primary reaction chambers with primary reaction oligonucleotide probes or primers each having a first portion comprising a nucleotide sequence complementary to a portion of target nucleic acids in the sample. In accordance with this embodiment, the primary reaction oligonucleotide probes or primers may further comprise a second portion comprising a nucleotide sequence the same as or complementary to a portion of a universal tag or capture oligonucleotide primers, retained within the mirco-pores or micro-wells.
A further aspect of the present invention relates to a method for preparing a system for identifying a plurality of nucleic acid molecules in a sample. The method involves providing a system of the present invention, where the system comprises an inlet port and a cartridge. The cartridge defines a space containing multiple primary reaction chambers fluidically coupled to the inlet port to receive material from the inlet port and produce primary reaction chamber products from the material; a product capture housing enclosing a solid support with a plurality of separate columns of a plurality of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual hydrophilic micro-pores or micro-wells separated by hydrophobic surfaces where primary reaction products are further reacted to create array products which are detected in the micro-pores or micro-wells, where one or more of the columns of separate product capture subunits receive material which has passed through one of the multiple primary reaction chambers; multiple secondary reaction chambers, one or more of which are fluidically coupled to one of the multiple primary reaction chambers to receive material from one of the multiple primary reaction chambers; and multiple mixing chambers each fluidically coupled to one of said multiple secondary reaction chambers to receive material from one of said multiple secondary reaction chambers and to discharge material to said product capture housing so that each column of separate product capture subunits is fluidically coupled to one of said one or more mixing chamber to receive material from one of said one or more mixing chambers. This method further involves applying universal tag or capture oligonucleotide primers or probes to the micro-pores or micro-wells of the product capture subunits on the solid support within the product capture housing. As a result, the universal tag or capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells.
This method may further involve filling the one or more primary reaction chambers and/or secondary reaction chambers with primary or secondary reaction oligonucleotide probes or primers each having a first portion comprising a nucleotide sequence complementary to a portion of target nucleic acids in the sample. In accordance with this embodiment, the primary or secondary reaction oligonucleotide probes or primers may further comprise a second portion comprising a nucleotide sequence which is the same as or complementary to a portion of a universal tag or capture oligonucleotide primers, retained within the micro-pores or micro-wells.
In one embodiment of the methods for preparing a system for identifying a plurality of nucleic acid molecules in a sample of the present invention, the product capture subunit comprises an array of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage in fluid communication with the second end of the micro-pores, where the universal tag or capture oligonucleotide primers or probes are applied to the micro-pores by a method comprising the following steps in the sequence set forth as follows: passing the universal tag or capture oligonucleotide primers or probes through the first passage into the micro-pores through their first open ends while hydrophobic liquid is passed through the second passage; passing a hydrophobic liquid through the first passage while the hydrophobic liquid is passed through the second passage; passing a volatile solvent through the first passage while the hydrophobic liquid is passed through the second passage; and passing air through the first passage while heat, a hydrophobic liquid, a volatile solvent, and then air is passed through the second passage.
In another embodiment of the methods for preparing a system for identifying a plurality of nucleic acid molecules in a sample of the present invention, the product capture subunit comprises an array of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage separated from the second end of the micro-pores by a mesh screen covering the second ends, in fluid communication with a second passage, where the detection or capture oligonucleotide primers or probes are applied to the micro-pores by a method comprising the following steps in the sequence set forth as follows: passing the universal tag or capture oligonucleotide primers or probes through the first passage into the micro-pores through their first open ends; passing a hydrophobic liquid through the first passage to expel the universal tag or capture oligonucleotide primers or probes from the first passage; passing a hydrophobic liquid through the first passage while a hydrophobic liquid is passed through the second passage; passing a volatile solvent through the first passage while a hydrophobic liquid is passed through the second passage; and passing air through the first passage while heat, a hydrophobic liquid, a volatile solvent, and then air is passed through the second passage.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. Following filling of the one or more primary reaction chambers and/or the one or more secondary reaction chambers, (if present), the process comprises conducting the primary and/or secondary reactions in the system and detecting the presence of target nucleic acid molecules in the sample in the micro-wells or micro-pores based on carrying out the primary and/or secondary reactions.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. Following the carrying out the primary and/or secondary reactions, the products of such reactions are amplified in the micro-wells or micro-pores under conditions where a polymerase, exonuclease, endonuclease, or ribonuclease cleaves one or more probes comprising a quencher and fluorescent group in a target-specific manner, such that fluorescent groups are liberated to generate signal if the target nucleic acid molecules are present in the sample.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. The process of conducting the primary and/or secondary reactions involves providing a sample containing a plurality of target nucleic acid molecules and contacting the sample with a set of primary oligonucleotide primers having a first portion complementary to a portion of the target nucleic acid molecule or a complement of the target nucleic acid molecule, and a polymerase to form a first polymerase extension or chain reaction mixture. This mixture is subjected to a first polymerase extension or chain reaction in the one or more initial or primary reaction chambers to produce a first set of extension or amplification products. These products are then contacted with a set of secondary oligonucleotide primers having a first portion complementary to a portion of a primary extension or amplification product and a polymerase to form a second polymerase chain reaction mixture. This second mixture is subjected to a second polymerase chain reaction in the primary or secondary reaction chambers to produce a second set of amplification products, where each secondary amplification product comprises a 5′ second portion sequence, a target nucleotide sequence-specific portion or its complement, and a 3′ second portion complementary sequence.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. The process of conducting the primary and/or secondary reactions involves providing a sample containing a plurality of target nucleic acid molecules and contacting the sample with a set of primary oligonucleotide primers having a portion complementary to a portion of the target nucleic acid molecule or its extension product and a polymerase to form a first polymerase extension or chain reaction mixture. This mixture is subjected to a first polymerase chain reaction in the one or more initial or primary reaction chambers to produce a first set of extension or amplification products. These products are then contacted with a set of oligonucleotide probes having a first portion complementary to a portion of the first set of amplification products and a second portion and a ligase to form a ligase detection reaction mixture. This second mixture is subjected to a ligase detection reaction in the primary or secondary reaction chambers to produce a set of ligation products, where each ligation product comprises a 5′ second portion sequence, a target nucleotide sequence-specific portion or its complement, and a 3′ second portion sequence.
Yet another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. The process of filling the one or more primary reaction chambers, if present, and the process of conducting the primary and/or secondary reactions in the system are carried out by a process involving the following steps in the sequence set forth as follows. Hydrophobic liquid is passed into the system through the inlet port. Primary reaction oligonucleotide probes or primers and reverse-transcription and/or polymerase chain reaction reagents and then hydrophobic liquid are passed into the system through the inlet port. A polymerase extension or chain reaction is carried out in the system and material is drained from the system through the inlet port. Hydrophobic liquid, polymerase chain reaction or ligase detection reaction reagents, and then hydrophobic liquid are passed into the system through the inlet port and a polymerase chain reaction or ligase detection reaction is carried out in the system.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention, where the product capture subunit comprises an array of individual micro-pores. The micro-pores each have opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage in fluid communication with the second end of the micro-pores and where said conducting the secondary reaction in the system is carried out by a process involving the following steps in the sequence set forth as follows. The products of a polymerase chain reaction or a ligase detection reaction are passed into the product capture housing through the first passage while passing hydrophobic liquid through the second passage. Hydrophobic liquid is then passed through the first and second passages. The products of the polymerase chain reaction or a ligase detection reaction are then subjected to a polymerase chain reaction with universal tag primers and probes within the micro-pores in the product capture subunit.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention, where the product capture subunit comprises an array of individual micro-pores. The micro-pores each have opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage in fluid communication with, and separated from, the second end of the micro-pores by a mesh screen covering the second ends of the micro-pores and where the process of conducting the secondary reactions in the system are carried out by a process involving the following steps in the sequence set forth as follows. The products of a polymerase chain reaction or a ligase detection reaction are passed into the product capture housing through the first passage. Hydrophobic liquid is passed through the first passage. Then, hydrophobic liquid is passed through the first and second passages. The products of the polymerase chain reaction or the ligase detection reaction are subjected to a polymerase chain reaction with universal tag primers and probes within the micro-pores in the product capture subunit.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention, where in a sample, a plurality of nucleic acid molecules containing a target nucleotide sequence differing from nucleotide sequences in other nucleic acid molecules in the sample, or other samples, by one or more nucleotides, one or more nucleotide insertions or deletions, one or more copy numbers, one or more transcript sequences, one or more translocations, and/or one or more methylated residues are identified.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention, where preparing the system involves filling the one or more primary reaction chambers with primary reaction oligonucleotide probes or primers each having a first portion comprising a nucleotide sequence complementary to a portion of target nucleic acids in the sample. Following the process of filling the one or more primary reaction chambers, the process further involves conducting the primary reaction in the system and obtaining the nucleotide sequence of target nucleic acid molecules in the sample following the process of conducting the primary reaction.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. The process comprises providing a sample containing a plurality of target nucleic acid molecules and contacting the sample with a set of primary oligonucleotide primers having a first portion complementary to a portion of the target nucleic acid molecules and a second portion and a polymerase to form a polymerase chain reaction mixture. This mixture is subjected to a polymerase chain reaction in the primary reaction chambers to produce a set of amplification products. The amplification products are passed to the product capture housing enclosing a solid support with a plurality of separate columns of a plurality of capture subunits with each separate product capture subunit comprising an array of a plurality of individual micro-pores containing immobilized capture probes complementary to the second portion. The target nucleic acid molecules are captured and copied onto the immobilized capture probes. The nucleotide sequence of the immobilized target nucleic acid molecules is obtained by carrying out sequencing reactions in the micro-pores.
In accordance with this embodiment, the product capture subunits may comprise an array of a plurality of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end. The process may further involve a mesh screen covering the second ends of the micro-pores in the product capture housing.
In another embodiment, the process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention further involves a bead containing the immobilized capture probes placed in the individual micro-pores.
In a further embodiment, the process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention further involves removing at least one second portion from the amplification product before the process of obtaining the nucleotide sequence and after the subjecting the polymerase chain reaction mixture to a polymerase chain reaction. The process of removing at least one second portion may be carried out with uracil DNA glycosylases, apurinic/apyrimidinic endonuclease, endonuclease III, endonuclease IV, endonuclease V, alkyladenine DNA glycosylase, formamidopyrimidine DNA glycosylase, or 8-oxyguanine DNA glycosylase, or combinations thereof.
Another embodiment relates to a process of identifying a plurality of nucleic acid molecules in a sample using the system of the present invention. The process involves providing a system of the present invention and applying universal tag or capture oligonucleotide primers or probes to the micro-pores or micro-wells of the product capture subunits on the solid support within the product capture housing, where the universal tag or capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells. The process further involves filling the one or more primary reaction chambers with primary reaction oligonucleotide probes or primers each having a first portion comprising a nucleotide sequence complementary to a portion of target nucleic acids in the sample and conducting the primary reaction in the system. The process further involves obtaining the nucleotide sequence of target nucleic acid molecules in the sample following the process of conducting the primary reaction. The product capture subunit comprises an array of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage in fluid communication with, and separated from, the second end of the micro-pores by a mesh screen covering the second ends of the micro-pores and where the process of obtaining the nucleotide sequence is carried by a process comprising the following steps in the sequence set forth as follows. The products of a polymerase chain reaction are passed into the product capture housing through said first passage. Hydrophobic liquid is then passed through the first passage, such that the products are distributed into individual micro-wells. Next, hydrophobic liquid is passed through the first and second passages. The products are amplified in a polymerase chain reaction and/or isothermal reaction using the capture oligonucleotide primers under conditions to generate amplification products that are immobilized to the interior surface of the micro-wells. A volatile solvent is then passed through the first passage while hydrophobic liquid is passed through the second passage. The products of the polymerase chain reaction and/or isothermal reaction are denatured, and non-anchored nucleic acid molecules are washed away through the first passage while hydrophobic liquid is passed through the second passages, such that the products are isolated in individual micro-wells. Hydrophobic liquid with a higher density than water is passed through the first passages while volatile solvent, air, and then sequencing reagents are passed through the second passages. A sequencing reaction is then carried out in the product capture subunit.
The present invention also relates to a process for preparing a microtiter plate for identifying a plurality of nucleic acid molecules in a sample. This involves providing a microtiter plate with a plurality of separate rows and columns of product capture subunits with each separate product capture subunit comprising an array of a plurality of individual hydrophilic micro-wells separated by hydrophobic surfaces. The micro-wells of the microtiter plate are filled with an aqueous liquid containing oligonucleotide primers and/or probes. The microtiter plate is centrifuged to spread the aqueous liquid to unfilled micro-wells in each separate product capture subunit in the microtiter plates. Centrifuging is then terminated to urge the aqueous liquid out of contact with the hydrophobic surfaces. The aqueous liquid is evaporated, and the micro-wells are dried so that the oligonucleotide primers are left in the micro-wells.
Another embodiment of the present invention relates to a process of identifying a plurality of nucleic acid molecules in a sample using the process of the present invention for preparing dried oligonucleotide primers within micro-wells of a microtiter plate. This involves charging an aqueous sample into the microtiter plate, followed by charging a hydrophobic liquid into the microtiter plate so that the hydrophobic liquid is over the aqueous sample. The microtiter plate is centrifuged to spread the aqueous liquid to unfilled micro-wells in the microtiter plate. Centrifuging is then terminated to urge the aqueous liquid out of contact with the hydrophobic surfaces. A nucleic acid molecule amplification reaction is carried out under conditions where a polymerase, exonuclease, endonuclease, or ribonuclease cleaves one or more probes comprising a quencher and fluorescent group in a target-specific manner, such that fluorescent groups are liberated to generate signal if the target nucleic acid molecules are present in the sample.
In accordance with this embodiment, a plurality of nucleic acid molecules containing a target nucleotide sequence differing from nucleotide sequences in other nucleic acid molecules in the sample, or other samples, by one or more nucleotides, one or more nucleotide insertions or deletions, one or more copy numbers, one or more transcript sequences, one or more translocations, and/or one or more methylated residues are identified.
Another aspect of the present invention relates to a system for identifying a plurality of nucleic acid molecules in a sample. This system comprises an inlet port; an outlet port; and a cartridge fluidically coupled to the inlet port and the outlet port. The cartridge defines a space containing a product capture housing enclosing a solid support with a plurality of separate columns of product capture subunits. Each separate product capture subunit comprises an array of a plurality of individual hydrophilic micro-pores separated by hydrophobic surfaces each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end. The product capture housing comprises a plurality of fluid channels to permit material to pass from the inlet port through a column of the product capture subunits into contact with the array of micro-pores in those subunits, and to the outlet port, where the plurality of fluid channels are located above and below the solid support.
In one embodiment, the system for identifying a plurality of nucleic acid molecules in a sample further comprises one or more valves for selectively introducing or removing reagents and/or reactants into or out of the product capture housing through the inlet port or through the outlet port.
In another embodiment for identifying a plurality of nucleic acid molecules in a sample, the system further comprises one or more heating elements in the cartridge proximate to the product capture housing.
The present invention relates to a method for preparing a system for identifying a plurality of nucleic acid molecules in a sample. This method involves providing a system of the presented invention, where the system comprises an inlet port, an outlet port, and a cartridge fluidically coupling the inlet port and the outlet port and defining a space, as described above. This method further involves applying capture oligonucleotide primers or probes to the micro-pores of the product capture subunits on the solid support within the product capture housing, where the capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells. In one embodiment, this method further involves conducting the reactions in the system and detecting the presence of target nucleic acid molecules in the sample in the micro-pores based on the conducting the reactions.
The present invention provides a set of devices, chambers, and assays for determining the cause of disease directly from a blood sample. Nucleic acids are purified from the clinical sample, targeted regions are subjected to a series of amplification reactions, and targets are identified or enumerated using either real-time PCR or sequencing as a readout. An overview of the urgent clinical needs that may be addressed by these devices is presented in Table 1.
One of the primary challenges for detecting multiple unknown pathogens or mutations is to amplify all potential and desired fragments simultaneously while avoiding PCR dropout in a multiplexed reaction. Multiplexed PCR reactions may be difficult to optimize, and fragment dropout has been a nagging problem. Often initial PCR cycles in the range of 8-12 cycles can maintain relative copy number, but when some fragments amplify more efficiently, they tend to out-amplify and overwhelm less efficient fragments resulting in fragment dropout at later cycles. One solution to this problem is to perform an initial limited cycle multiplexed amplification, and then divide the products into 24 to 48 reaction chambers for subsequent amplification reactions at far lower complexity. An additional solution is to dilute the initial amplification products into subdivisions comprising tens, hundreds, or thousands of micro-pores or micro-wells. A given micro-pore or micro-well may then be used for 1 to 4 qPCR or individual sequencing reactions, thus allowing for accurate target enumeration or quantification, while minimizing the risks of PCR dropout.
One aspect of the invention is a set of subdivisions, preferably arranged in rows and columns, each subdivision comprising of single digits, tens, hundreds, or thousands of micro-pores or micro-wells for subsequent qPCR, UniTaq, FRET, qLDR, or sequencing reactions and target identification. In the preferred embodiments, the presence of target results in a fluorescence readout. In some embodiments, the target is amplified and immobilized or coupled to a solid support within the micro-pores or micro-wells. Such immobilization may occur directly on the interior surface on the micro-pores or micro-wells, on dendrimeric primers immobilized to the surface of the micro-pores or micro-wells, or on micro-beads that are either already distributed within micro-pores or micro-wells prior to amplification or are distributed into micro-pores or micro-wells after the initial amplification Immobilization or coupling to the solid support enables interrogating the amplified target one or more times to determine the presence or absence of mutations, SNPs, or sequence variations within the target. This includes multiple rounds of ligation detection reactions (LDR), sequencing by synthesis, or sequencing by ligation.
Arrangement of subdivisions in rows and columns facilitates filling such rows and columns with either universal or target-specific primers, enzymes, reagents, buffers, targets, or pre-amplified targets. Filling may be accomplished by flowing liquids across all subdivisions in given rows or columns through fluidically coupled or connected channels, or alternatively by accurately dispensing liquids to individual subdivisions, e.g. using acoustic droplet ejection (ADE) technology. One manufacturer of ADE equipment is Labcyte (Sunnyvale Calif.).
In one embodiment of the current invention, this flexible design architecture enables identification, genotyping, and/or quantification of viral, bacterial, protozoal, malarial, or other pathogenic nucleic acids representing potentially 384, 768, or 1536 targets, mutations, resistance genes, pathogenesis genes and/or strain or serotype variants. Detecting bacterial DNA directly from blood is a particularly difficult challenge, since yields are typically on the order of 1-2 colony forming units per ml of blood; however, the spatial multiplexing approach may still enable identification of 32, 64, or 128 potential targets. When using the sequencing module as described below, the design enables determining about 150 base reads for 1,536 potential pathogenic targets.
Another embodiment of the design uses spatial dilution (e.g. into 48 sections) to enable accurate enumeration of copy number directly from plasma for non-invasive pre-natal testing for trisomy (NIPT). Since the Watson strands should match the Crick strands in each of the 48 sections, i.e. columns (since they are generated from a given fragment with one of each strand), this is an internal control for loss of strands or other errors. Multiple unique loci on Chromosomes 2 (control), 13, 18, 21, X, and Y are used to establish copy number and discern trisomy or other chromosomal copy changes. In one embodiment, 184 locus regions could be interrogated on both strands, but this could be increased to 368 or 736 locus regions.
Another embodiment of the design enables PCR-LDR-qPCR single-molecule mutation detection directly from plasma for up to 64 or 128 potential targets, with additional flexibility when multiple mutations in a gene (i.e. the mutations in K-ras codons 12 & 13) are scored by a single signal. A similar level of flexibility may be applied for identifying and enumerating methylation of CpG sites in the promoter region of selected genes. The ability to perform serial dilutions within the chambers enables exact enumeration of 384 RNA targets, including rare and overexpressed lncRNA, mRNA, or splice variants, for example isolated from exosomes or platelets.
Another embodiment of the design enables determining low abundance mutations in 144 target regions, providing about 150 base reads for both strands, with accurate enumeration of each mutation. Sequencing methylated regions allows for pre-enrichment of these areas, such that over 2,000 methylated CpG promoter regions could be interrogated, even if present at low abundance.
In one embodiment of the invention (see
In another embodiment of the invention (
In another variation of the above embodiment, the subdivisions Z are 400-micron wide×600-micron long, with 100-micron wide ridges X and Y between subdivisions. The dimensions of the micro-pores or micro-wells may be 2.5-micron diameter, ranging from about 2.5-micron deep to 20-micron deep, and may be open (i.e. micro-pores) or closed (i.e. micro-wells) at the bottom. The bottom of the 2.5-micron micro-pores may have another layer of 0.5-micron holes on silicon nitride 200 to 400-nanometers thick, enabling filling of the 2.5-micron micro-pores with liquid from the top, allowing air, but not liquid to escape through the 0.5-micron pores at the bottom. In one embodiment, each subdivision comprises 100×92=11,040 micro-pores or micro-wells of 2.5-micron diameter, generated in hexagonal packing. Such an embodiment is ideally suited for subsequent sequencing by synthesis, or sequencing by ligation.
In another embodiment of the invention (see
In another embodiment of the invention (See
In another variation of the above embodiment, the subdivisions are 400 micron wide×600-micron long, with 100-micron wide ridges between subdivisions. The dimensions of the micro-pores or micro-wells may be 2.5-micron diameter, ranging from about 2.5-micron deep to 20-micron deep. The bottom of the 2.5-micron micro-pores may have another layer of 0.5-micron holes on silicon nitride 200 to 400-nanometers thick, enabling filling of the 2.5-micron micro-pores with liquid from the top, allowing air, but not liquid to escape through the 0.5-micron pores at the bottom. In one embodiment, each subdivision comprises 100×92=11,040 micro-pores of 2.5-micron diameter, generated in hexagonal packing. Such an embodiment is ideally suited for subsequent sequencing by synthesis, or sequencing by ligation.
The devices are envisioned to comprise an array of micro-pores or micro-wells, that are fluidically connected to micro-fluidic channels. In one embodiment, the fluidically connected channels feed various reagents and enzymes into a series of reaction chambers to enable pre-amplification reactions prior to moving the products into the array of micro-pores or micro-wells, for subsequent Taqman™ or sequencing readout.
The left (bottom) portion of
The left (bottom) portion of
In one embodiment of
Both
In the sections below, descriptions are provided of the different micro-fluidic chamber architecture, as well as illustrations of how the various chambers, micro-wells, and/or micro-pores are filled with liquids suitable for subsequent nucleic acid amplification, detection, and/or sequencing reactions.
Alternative configurations for micro-wells or micro-pores may also be considered. OpenArray technology is available through ThermoFisher (Carlsbad, Calif.). This technology uses a metal microscope slide-sized plate with 3,072 through-holes, which may be configured into a variety of different ways. For example, the plate may be divided into 48 subarrays with 64 through-holes or micro-pores (each subarray is in the same spacing as a traditional 384 well microtiter plate. As currently configured, each through-hole is 300-microns in diameter and 300-micron deep, wherein the through-hole is hydrophilic or has a hydrophilic coating, but the front and back surface of the plate has a hydrophobic coating. Thus, aqueous reagents are retained in the through-holes via surface tension. After filling the through holes with the appropriate amplification and detection primers, these primers may be dried onto the inner surface of the through-holes. Subsequently, addition of the sample, enzymes, and appropriate buffer solubilizes the primers, while use of hydrophobic liquid (i.e. mineral oil) on both sides seals the reactions in place in each through-hole. This technology could be extended by manufacturing the through-holes with 60-micron diameter, which would enable about 1,225 through-holes per subarray for a total of 58,800 through-holes or micro-pores per microscope slide-sized plate. Another system, also developed by ThermoFisher is the QuantStudio 3D digital PCR 20K Chip, comprising of a silicon substrate that has been etched to contain 20,000 micro-wells of 60-micron diameter. Primers, reagents, and enzyme are added, the plate is sealed to distribute the liquid into the micro-wells, and the reaction is run—the limitation being that only a single reaction may be performed on the chip. Another system is being developed by Formulatrix (Bedford, Mass.) and is known as the Constellation Digital PCR system. In this system, a standard microtiter plate is divided into either 24 chambers comprising 32,000 micro-wells (of about 50-micron diameter) or 96 chambers comprising 8,000 micro-wells. This design is also compatible with use of 24 chambers comprising 200,000 micro-wells (of about 20-micron diameter), 96 chambers comprising 50,000 micro-wells, or 384 chambers comprising 12,500 micro-wells. Each chamber has an input well that is fluidically coupled to an input channel, which is fluidically coupled to numerous connecting channels comprising of individual partitions, and then all the connecting channels are fluidically coupled to an output channel, which has a vent or air-hole. At the bottom of the channel is a clear plastic suitable for sealing to the plate. Primers, reagents, and enzyme are added to the input well and fluidically pumped through the input channel, and the connecting channels, with excess moving into the output channel and vent. Subsequently, a roller is used to compress the bottom seal, which blocks off the channels, such that each partition becomes an isolated micro-well suitable for thermocycling and digital PCR readout. This system may be modified, such that the bottom plastic only forms a temporary seal, either by using pressure to temporarily block off the connecting channels and create the partitions (micro-wells) only during the amplification reaction, or a temporary sealant that may be subsequently dissolved. For subsequent sequencing reactions, after amplification and immobilization of targets in individual partitions (micro-wells), the bottom plastic may be unsealed, unreacted reagent and products that are not covalently immobilized may be denatured and washed away. The resulting clonally amplified single-stranded targets are suitable for subsequent sequencing-by-synthesis reactions, as described below or as known in the art.
One aspect of the present invention is directed to a method for identifying, in a sample, a plurality of nucleic acid molecules containing a target nucleotide sequence differing from nucleotide sequences in other nucleic acid molecules in the sample, or other samples, by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues. This method involves providing a sample potentially containing one or more nucleic acid molecules containing the target nucleotide sequence differing from the nucleotide sequences in other nucleic acid molecules by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues. One or more primary oligonucleotide primer sets are provided, each primary oligonucleotide primer set comprising (a) a first primary oligonucleotide primer that comprises a nucleotide sequence that is complementary to a sequence adjacent to the target nucleotide sequence, and (b) a second primary oligonucleotide primer that comprises a nucleotide sequence that is complementary to a portion of an extension product formed from the first primary oligonucleotide primer. The contacted sample is blended with the one or more primary oligonucleotide primer sets, a deoxynucleotide mix, and a DNA polymerase to form a polymerase chain reaction mixture, and the polymerase chain reaction mixture is subjected to one or more polymerase chain reaction cycles comprising a denaturation treatment, a hybridization treatment, and an extension treatment, thereby forming primary extension products comprising the target nucleotide sequence or a complement thereof. The initial PCR products are distributed into 24, 36, or 48 Primary PCR Reaction Chambers. The method further involves blending the primary extension products with a polymerase, and one or more secondary oligonucleotide primer sets to form a secondary polymerase reaction mixture. Each secondary oligonucleotide primer set comprising (a) a first secondary oligonucleotide primer that comprises a 5′ primer-specific portion and a nucleotide sequence that is complementary to a sequence adjacent to and/or comprising the target nucleotide sequence, and (b) a second secondary oligonucleotide primer that comprises a 5′ primer-specific portion and a nucleotide sequence that is complementary to a portion of an extension product formed from the first secondary oligonucleotide primer. The contacted sample is blended with the one or more secondary oligonucleotide primer sets, a deoxynucleotide mix, and a DNA polymerase to form a polymerase chain reaction mixture, and the polymerase chain reaction mixture is subjected to one or more polymerase chain reaction cycles comprising a denaturation treatment, a hybridization treatment, and an extension treatment, thereby forming primary extension products comprising the target nucleotide sequence or a complement thereof. The secondary extension product sequences in the sample are detected and distinguished to identify the presence of one or more nucleic acid molecules containing target nucleotide sequences differing from nucleotide sequences in other nucleic acid molecules in the sample by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues.
As shown in
The UniTaq system is fully described in U.S. Patent Application Publication No. 2011/0212846 to Spier, which is hereby incorporated by reference in its entirety. The UniTaq system involves the use of three unique “tag” sequences, where at least one of the unique tag sequences (Ai) is present in the first oligonucleotide primer, and the second and third unique tag portions (Bi and Ci) are in the second oligonucleotide primer sequence as shown in
As shown in
The double stranded PCR products are denatured, and when the temperature is subsequently decreased, the upper strand of product forms a hairpin having a stem between the 5′ portion (Bi) of the first oligonucleotide primer and portion Bi′ at the opposite end of the strand (
The split probe system is fully described in U.S. Pat. No. 9,598,728 to Barany et al., which is hereby incorporated by reference in its entirety. Herein, a split probe system designed for PCR amplification that involves the use of four unique “tag” sequences, where the first unique tag sequence (Ai) and split portions of the second and third unique tag portions (Bi′, ti′), are present in the first secondary oligonucleotide primer, and the other split portions of second and third unique tag portions (tj and Bj), as well as the fourth unique tag sequence (Ci) are in the second secondary oligonucleotide primer sequence as shown in
As shown in
The double stranded PCR products are denatured, and when the temperature is subsequently decreased, the upper strand of product forms 4 hairpins form between pathogen-specific sequences (ti & ti′; tj & tj′), Bi & Bi′, and Bj & Bj′. This renders the ribose base in the Bj sequence double-stranded, enabling RNaseH2 to liberate the fluorescent group F1 label from the product, thereby increasing the distance between the label and the quencher and permitting detection of the label (
Another aspect of the present invention is directed to a method for identifying, in a sample, a plurality of nucleic acid molecules containing a target nucleotide sequence differing from nucleotide sequences in other nucleic acid molecules in the sample, or other samples, by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues. This method involves providing a sample potentially containing one or more nucleic acid molecules containing the target nucleotide sequence differing from the nucleotide sequences in other nucleic acid molecules by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues. One or more primary oligonucleotide primer sets are provided, each primary oligonucleotide primer set comprising (a) a first primary oligonucleotide primer that comprises a nucleotide sequence that is complementary to a sequence adjacent to the target nucleotide sequence, and (b) a second primary oligonucleotide primer that comprises a nucleotide sequence that is complementary to a portion of an extension product formed from the first primary oligonucleotide primer. The contacted sample is blended with the one or more primary oligonucleotide primer sets, a deoxynucleotide mix, and a DNA polymerase to form a polymerase chain reaction mixture in an Initial Reaction Chamber, and the polymerase chain reaction mixture is subjected to one or more polymerase chain reaction cycles comprising a denaturation treatment, a hybridization treatment, and an extension treatment, thereby forming primary extension products comprising the target nucleotide sequence or a complement thereof. The initial PCR products are distributed into 24, 36, or 48 Primary LDR Reaction Chambers. The method further involves blending the primary extension products with a ligase and one or more oligonucleotide probe sets to form a ligation reaction mixture. Each oligonucleotide probe set comprises (a) a first oligonucleotide probe having a target nucleotide sequence-specific portion, and (b) a second oligonucleotide probe having a target nucleotide sequence-specific portion, wherein the first and second oligonucleotide probes of a probe set are configured to hybridize, in a base specific manner, adjacent to one another on a complementary target nucleotide sequence of a primary extension product with a junction between them. The first and second oligonucleotide probes of the one or more oligonucleotide probe sets are ligated together to form ligated product sequences in the ligation reaction mixture, and the ligated product sequences in the sample are detected and distinguished to identify the presence of one or more nucleic acid molecules containing target nucleotide sequences differing from nucleotide sequences in other nucleic acid molecules in the sample by one or more nucleotides, one or more copy numbers, one or more transcript sequences, and/or one or more methylated residues.
As shown in
The UniTaq system is fully described in U.S. Patent Application Publication No. 2011/0212846 to Spier, which is hereby incorporated by reference in its entirety. The UniTaq system involves the use of three unique “tag” sequences, where at least one of the unique tag sequences (Ai) is present in the first oligonucleotide probe, and the second and third unique tag portions (Bi′ and Ci′) are in the second oligonucleotide probe sequence as shown in
After ligation, the ligation products of each Primary LDR Reaction Chamber are distributed into 384 or 768 micro-wells or micro-pores that contain the appropriate UniTaq primer pairs (
The double stranded PCR products are denatured, and when the temperature is subsequently decreased, the upper strand of product forms a hairpin having a stem between the 5′ portion (Bi) of the first oligonucleotide primer and portion Bi′ at the opposite end of the strand (
The split probe system is fully described in U.S. Pat. No. 9,598,728 to Barany et al., which is hereby incorporated by reference in its entirety. The split probe system involves the use of four unique “tag” sequences, where the first unique tag sequence (Ai) and split portions of the second and third unique tag portions (Bi′, zi), are present in the first oligonucleotide probe, and the other split portions of second and third unique tag portions (zi′, Bj′), as well as the fourth unique tag sequence (Ci′) are in the second oligonucleotide probe sequence as shown in
After ligation, the ligation products of each Primary LDR Reaction Chamber are distributed into 384 or 768 micro-wells or micro-pores that contain the appropriate UniTaq primer pairs (
The double stranded PCR products are denatured, and when the temperature is subsequently decreased, the upper strand of product forms 3 hairpins between Bi & Bi′, zi & zi′, and Bj & Bj′ (
Both the UniTaq probe and the split probe approach provide the advantage of allowing a standard set of primers/probes to be printed in the appropriate micro-pores or micro-wells. Note that the Ci primer will make copies of the downstream LDR probe, independent of whether it was ligated to form a product or remained unligated. If that extension product forms a primer dimer with the upstream probe/primer in the absence of target using the UniTaq probe design, such a product (F1-Bi-Q-Ai-partial target-Bi′-Ci′) would allow for the Bi & Bi′ hairpin to form at the hybridization temperature, and then give a false-positive signal. One advantage of the split probe design is that such a false product (F1-Bj, Bi-Q-Ai-partial target-zi′, Bj′-Ci′) would not give a false-positive signal since it would not form the Bi & Bi′, zi & zi′ hairpins, leaving only the Bj & Bj′ sequences, which would not form a stem at the hybridization temperature used in the amplification reaction.
The ligation products may also be used to generate signal directly in a process termed PCR-qLDR, as exemplified below in
In one embodiment, the first ligation probe contains a 3′ target specific region and a 5′ tail sequence with a donor or acceptor moiety and the second ligation probe in a probe set contains a 5′ target specific region and 3′ tail sequence with an acceptor or donor moiety, respectively. The 5′ and 3′ tail sequences of the ligation probes in a probe set are complementary to each other and the acceptor and donor groups generate a detectable signal via Förster Resonance Energy Transfer (FRET) when brought in close proximity to each other. Following ligation, unligated oligonucleotide probes are washed away, and the ligation product is denatured from the immobilized amplification products. Upon denaturation, the complementary 5′ and 3′ tail sequences of the ligation products hybridize to each other bringing the donor and acceptor groups in close proximity to each other to generate a detectable FRET signal.
In another embodiment, the upstream probe may contain a fluorescent reporter group on the 5′ end followed by the tail sequence portion, a quenching group (e.g., ZEN), and the target-specific portion. In the single-stranded form, the fluorescent group is quenched by the Zen group. Upon ligation of the upstream and downstream ligation probes and denaturation of the resulting the ligation product, the complementary 5′ and 3′ tail portions of the ligation product hybridize to form a short double stranded portion. Under these conditions, the reporter group is no longer quenched by the quenching group and a detectable signal is produced. This is referred to as a hybridization unquenching probe (HuQP).
An approach for qLDR that does not require PCR is termed “Multiple Ligase Reactions and Probe Cleavages for SNP Detection”—(Kim, “PCR Free Multiple Ligase Reactions and Probe Cleavages for the SNP Detection of KRAS Mutation with Attomole Sensitivity,” Analyst 141(16):6381-6386 (2016), which is hereby incorporated by reference in its entirety). In this approach, two primers are hybridized to, and ligated on a target if there is perfect complementarity with the target at the junction. The two primers also contain non-complementary sequences on their non-ligating 3′ and 5′ ends. After ligation, the ligation products (LP's) are complexed with a strand displacing hairpin (SDH) due to the higher melting temperature (Tm) of the LP with the SDH than with the target. The free target then can be recycled for a new ligation with the two primers. The addition of the SDH to the ligase reaction allows multiple enzymatic ligations of the two primers for each single target during the isothermal condition. To generate a detectable signal, the SNP-specific ligation is followed by a modified cycling probe assay with gold nanoparticles (AuNPs). In the cycling probe assay, the target-bound chimeric probe with a fluorescent donor and quencher at either end is digested with RNase H. RNase H cleaves RNA phosphodiester bonds only when they present in an RNA-DNA heteroduplex; it does not digest the DNA in the heteroduplex, nor does it digest single- or double-stranded RNA or DNA. The cycling probe assay is designed to utilize these properties of RNase H. When the target DNA strand becomes free upon RNA degradation, another intact RNA molecule can hybridize with the DNA, leading to linear signal amplification.
Pathogen-specific ligation oligonucleotides have tags (Bi′-ti′-upstream target sequence; downstream target sequence-tj′-Bj′) for subsequent detection. The ti′ and tj′ sequences are complementary to sequences ti, tj in the target at the ligation junction. When detecting specific SNPs or mutations, blocking LNA or PNA wild-type probes suppress ligation to wild-type sequence. As illustrated in step D of this figure, another layer of specificity can be incorporated into the method by including a 3′ cleavable blocking group (Blk 3′, e.g. C3 spacer), and an RNA base (r), in the upstream ligation probe. Upon target-specific hybridization, RNase H (star symbol) removes the RNA base to generate a ligation competent 3′OH group (
In the presence of probe (F1-r-Bj, Bi-Q), and after the denaturation step, as the temperature decreases, 4 double-stranded stems form between probe and pathogen-specific sequences (ti & ti′; tj & tj′), Bi & Bi′, and Bj & Bj′. This renders the ribose base in the Bj sequence double-stranded, enabling RNaseH2 to liberate the fluorescent group and generate signal (
Pathogen-specific ligation oligonucleotides have tags (Bi′-upstream target sequence; downstream target sequence-tj′) for subsequent detection. The tj′ sequence is complementary to the tj sequence in the target at the ligation junction. When detecting specific SNPs or mutations, blocking LNA or PNA wild-type probes suppress ligation to wild-type sequence. As illustrated in step D of this figure, another layer of specificity can be incorporated into the method by including a 3′ cleavable blocking group (Blk 3′, e.g. C3 spacer), and an RNA base (r), in the upstream ligation probe. Upon target-specific hybridization, RNase H (star symbol) removes the RNA base to generate a ligation competent 3′OH group (
In the presence of probe (F1-r-pathogen sequence-Bi-Q), and after the denaturation step, as the temperature decreases, 2 double-stranded stems form between pathogen-specific sequences (ti,tj & ti′,tj′), and Bi & Bi′. This renders the ribose base in the pathogen sequence double-stranded, enabling RNaseH2 to liberate the fluorescent group and generate signal. The cleaved probe dissociates from the product and new probe can hybridize to generate additional signal. Unligated LDR primers would not form both stems, and thus RNaseH2 would not liberate signal. In one embodiment of this approach, after the PCR reaction, products are distributed into micro-wells or micro-pores, which already contain the target-specific LDR primers, as well as the pathogen sequence specific probe(s).
To what extent does qLDR with a cleavable probe (cP) generate more signal than when using LDR with either a FRET probe, or hybridization unquenching (HuQP) probe. The latter generates a linear signal as a function of cycle, i.e. if running “X” cycles of LDR, then amount of fluorescent signal generated “F” is proportional to X; i.e. F=f(X). When using the cleavable probe as in
The cartridge design of
In an alternative embodiment using 48 columns and 48 rows equaling 2,304 subdivisions, each subdivision comprising 96 micro-wells, 1-4 UniTaq primer sets (or alternatively, 1-4 universal tag primer sets with target-specific Taqman™ probes) are delivered directly to the appropriate subdivision in each row by acoustic droplet ejection, capillary, inkjet, or quill printing, and then dried down into individual micro-wells. The initial multiplexed PCR amplification (or reverse-transcription-PCR for RNA targets) is for 10 cycles to generate up to 1,024 copies of each original target in an Initial Reaction Chamber or well. If needed, use “tandem” PCR primers. Fresh PCR reagents are added, and the initial multiplexed reaction is distributed into 48 wells or Primary PCR Reaction Chambers (with nested PCR primers added using acoustic droplet ejection), with average distribution of 20 copies of each original pathogen per well or Primary PCR Reaction Chamber. Optionally, primers containing an RNA base and 3′ blocking group are unblocked with RNaseH2 only when bound to the correct target, providing additional specificity and avoiding false products. Perform 3-4 cycles of nested PCR using target-specific primers with UniTaq or universal tags in groups of 24, or 48 primer sets, to generate an average of 160-320 copies of each pathogen-specific target per well or Primary PCR Reaction Chamber. Fresh PCR reagents are added, mixed with the nested PCR products of each well or Primary PCR Reaction Chamber, and distribute products of each well or Primary PCR Reaction Chamber into 2 or 4 sets of 24 or 12 subdivisions respectively containing 96 micro-wells. When using 2 sets, the second set is a 100/1 dilution of the first. When using 4 sets, each set is a 20/1 dilution of the previous set. This allows coverage of pathogens present across many orders of magnitude. On average, each initial subdivision will get 12 copies of each original pathogen, with a given micro-well getting one or zero copies of original pathogen. If pathogen is present in higher numbers, each subdivision will get additional copies. Universal or UniTaq primers in each subdivision of each row will amplify only those products from each column with the correct tags. Poisson distribution in 96 micro-wells will enumerate pathogen-specific targets initially present at low abundance, while Ct values across micro-wells in a subdivision will provide approximate copy information for pathogen-specific targets initially present at high abundance.
As shown in
As shown in
The cartridge design of
In an alternative embodiment using 48 columns and 48 rows equaling 2,304 subdivisions, each subdivision comprising 96 micro-wells, 1-4 UniTaq primer sets (or alternatively, 1-4 universal tag primer sets with target-specific Taqman™ probes) are delivered directly to the appropriate subdivisions in each row by acoustic droplet ejection, capillary, inkjet, or quill printing, and then dried down into individual micro-wells. Initial sample is distributed into 48 wells. 9 cycles of multiplexed PCR are performed in a well or an Initial Reaction Chamber, maximum of 512 copies of each original pathogen, if present. Use “tandem” or more PCR primer sets. Also, all PCR primers include identical 5′ tail sequences, preferably 10-12 bases to suppress amplification of primer dimers. On average, each initial subdivision will get 10 copies of each original pathogen, with a given micro-well getting one or zero copies of original pathogen. If pathogen is present in higher numbers, each subdivision will get additional copies. Universal or UniTaq primers in each subdivision of each row will amplify only those products from each column with the correct tags. Poisson distribution in 96 micro-wells will enumerate pathogen-specific targets initially present at low abundance, while Ct values across micro-wells will provide approximate copy information for pathogen-specific targets initially present at high abundance.
As shown in
As shown in
In an alternative embodiment using 48 columns and 48 rows equaling 2,304 subdivisions, each subdivision comprising 96 micro-wells, 1-4 UniTaq primer sets (or alternatively, 1-4 universal tag primer sets with target-specific Taqman™ probes) are delivered directly to the appropriate subdivisions in each row by acoustic droplet ejection, capillary, inkjet, or quill printing, and then dried down into individual micro-wells. Distribute initial sample into 48 wells or Primary PCR Reaction Chambers 16. Highest level of DNA in plasma=10,000 genome equivalents. On average, 200 copies of each target per Primary PCR Reaction Chamber 16, with at most 1 mutation. Perform 10-40 cycles of locus-specific PCR with blocking PNA or LNA to reduce amplification of wild-type DNA. Optional: Use dUTP during PCR reaction (and pre-treat with UDG to avoid carryover contamination of initial sample). Optionally, either PCR primers and/or LDR upstream probes containing an RNA base and 3′ blocking group are unblocked with RNaseH2 only when bound to the correct target, providing additional specificity and avoiding false products. Also, all downstream PCR primers include identical 5′ tail sequences, preferably 8-11 bases to suppress amplification of primer dimers. In another embodiment, to minimize dropout of fragments during multiplexed PCR, an initial “pre-amplification” multiplexed PCR is performed for 8-20 cycles in an initial well or reaction chamber. These products are then distributed into 48 wells or Primary PCR Reaction Chambers 16. In one variation, each of the 48 wells or primary reaction chambers contains from 1-4 PCR primer sets with PNA or LNA to suppress amplification of wild-type sequence, and single or multiplexed PCR is performed for an additional 10-30 cycles to enable amplification of 1-4 different fragments containing potential mutations in a single well or primary reaction chamber. In another variation, 12 sets of 4 primary reaction chambers contains from 4-16 PCR primer sets with PNA or LNA to suppress amplification of wild-type sequence, and multiplexed PCR is performed for an additional 10-30 cycles to enable amplification of 4-16 different fragments containing potential mutations in a single well or primary reaction chamber. Dilute products of each well with LDR primers and buffers. Perform 20 cycles of LDR using allele-specific primers with UniTaq tails, in groups of 16, 32, or 64 primer sets in wells or Secondary LDR Reaction Chamber 22. LDR primers for different mutations of the same gene may be designed to give the same signal in the same subdivision. LDR reactions may be performed in the same reaction chamber, or in 2 separate reaction chambers, and then re-combined. Add UniTaq master mix and UDG and distribute products of each well or Secondary LDR Reaction Chamber 22 into 48 subdivisions respectively containing 96 micro-pores. The subdivisions have been pre-spotted with appropriate UniTaq primers, and/or probes; (see
The cartridge and valve setup of
As shown in
The cartridge design of
The cartridge and valve setup of
As shown in
In an alternative embodiment using 48 columns and 48 rows equaling 2,304 subdivisions, each subdivision comprising 96 micro-wells, 1-4 UniTaq primer sets (or alternatively, 1-4 universal tag primer sets with target-specific Taqman™ probes) are delivered directly to the appropriate subdivisions in each row by acoustic droplet ejection, capillary, inkjet, or quill printing, and then dried down into individual micro-wells. Perform 10 cycles of multiplexed RT-PCR, maximum of 1,024 copies of each original RNA molecule in the Initial Reaction Chamber or well. If needed, use “tandem” PCR primers. Also, all PCR primers may include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers. Distribute initial multiplexed products into 48 wells or Primary PCR Reaction Chambers. Average distribution in each well is 20 copies of each original RNA target. Perform 3-4 cycles of nested PCR using primers with UniTaq tails, in groups of 24, or 48 primer sets, for a maximum of 160-320 copies of each original pathogen. Distribute products of each well into 2 or 4 sets of 24 or 12 subdivisions respectively containing 96 micro-pores. When using 2 sets, the second set is a 100/1 dilution of the first. When using 4 sets, each set is a 20/1 dilution of the previous set. This allows coverage of RNA molecules present across many orders of magnitude. On average, each initial subdivision will get 12 copies of each original RNA molecule, with a given micro-pore getting one or zero copies of original RNA. If RNA is present in higher numbers, each subdivision will get additional copies. PCR amplify 1, 2, or 4 potential products in each micro-pore using the pre-spotted UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers. Poisson distribution in 96 micro-pores across 2 or 4 dilution sets will provide some degree of enumeration for very low copy RNA, as well as higher copy RNA in sample.
Another embodiment of the present invention is a system for sequencing by synthesis or by ligation of target molecules on a solid support. One or more target molecules are amplified within a 5-micron diameter micro-pore, for example as described in
Standard approaches for detecting sequencing-by-synthesis fluorescent product depend on amplifying only one target per well and using a single universal primer to generate sequencing reads. One approach for amplifying single target molecules is to immobilize both forward and reverse primers on a solid support, known as cluster amplification. However this approach limits total yield of strands within a cluster, since extension products tend to re-hybridize with each other rather than with fresh primers. An alternative approach is to amplify DNA on beads within aqueous droplets, surrounded by oil. Herein, a simpler approach is proposed, wherein the amplification takes place in solution, and products are then captured on the solid support, or on immobilized primers, that are then extended to make copies of the amplified products. This allows for the reactions to take place in larger volumes, resulting in higher yields of multiple amplified products, that may then be sequenced using selected target-specific primers, or alternatively, different sets of sequencing primers comprising of common and variable regions. For each round of sequencing, with appropriate loading and primer selection, about 30%-35% of the micro-pores will provide a unique sequencing read.
The micro-pores and micro-wells are constructed to have hydrophilic surfaces within and hydrophobic surfaces on the outside. This architecture is suitable for drawing the sample fluids into discrete isolated volumes of liquids, enabling amplification without cross-talk between micro-pores or micro-wells. Further, the hydrophilic surface can be functionalized for attachment/immobilization of primers within the micro-pores or micro-wells, but not outside so there can be no cross-talk.
When the solid support is comprised of Poly(methyl methacrylate)—(a.k.a. PMMA, Plexiglass, Lucite)—, cyclic olefin copolymer (COC), polyethylene, or polypropylene sheeting one approach is to create the micro-pores or micro-wells via UV laser ablation. Alternatively, the micro-pores and micro-wells are created via injection molding, imprinting, hot embossing, or etching, and those specific surfaces exposed to UV light using a masking approach. These processes generate a carboxylate surface, suitable for EDC/NHS mediated covalently linkage of 5′ amino-terminated oligonucleotides to generate micro-arrays (Situma et al., “Fabrication of DNA Microarrays onto Poly(methyl Methacrylate) with Ultraviolet Patterning and Microfluidics for the Detection of Low-abundant Point Mutations,” Anal Biochem 340(1):123-35 (2005); McCarley et al., “Resist-free Patterning of Surface Architectures in Polymer-based Microanalytical Devices,” J Am Chem Soc. 127(3):842-3 (2005); Soper et al., “Fabrication of DNA Microarrays onto Polymer Substrates Using UV Modification Protocols With Integration Into Microfluidic Platforms for the Sensing of Low-abundant DNA Point Mutations,” Methods 37(1):103-13 (2005); Wang et al., “Microarrays Assembled in Microfluidic Chips Fabricated From Poly(Methyl Methacrylate) for the Detection of Low-Abundant DNA Mutations,” Anal Chem. 75(5):1130-40 (2003), which are hereby incorporated by reference in their entirety).
In an alternative embodiment, covalently attached polymer brushes are grown on the surface of PMMA by atom transfer radical polymerization (ATRP) (Balamurugan et al., “Aqueous-based Initiator Attachment and ATRP Grafting of Polymer Brushes from Poly(Methyl Methacrylate) Substrates,” Langmuir 28(40):14254-60 (2012), which is hereby incorporated by reference in its entirety). This approach is based on the covalent immobilization of an ATRP initiator on PMMA surfaces and subsequent surface-initiated aqueous ATRP formation of Poly(N isopropylacrylamide) PNIPAAm. Briefly, selected regions of PMMA are UV modified to introduce carboxylic acid functional groups, which are subsequently converted to amino groups by reacting with ethylenediamine in EDC/NHS. These amine-functionalized PMMA surfaces are then reacted with the activated ester of the ATRP initiator; N-hydroxysuccinimidyl-2-bromo-2-methylpropionate. From the covalently attached initiator surfaces, atom-transfer polymerization in water is carried out to grow PNIPAAm brushes. This aqueous-based route to grafting polymers from surfaces can be adaptable to a variety of substrates and water-soluble ATRP monomers.
In an alternative embodiment, COC surfaces were photografted with poly(ethylene glycol) methacrylate (PEGMA) using a two-step sequential approach: covalently-bound surface initiators are formed in the first step and graft polymerization of PEGMA is then carried out from these sites in the second step. (Stachowiak et al., “Hydrophilic Surface Modification of Cyclic Olefin Copolymer Microfluidic Chips Using Sequential Photografting,” J Sep Sci. 30(7):1088-93 (2007), which is hereby incorporated by reference in its entirety). A similar approach is also used for low-density polyethylene films. (Wang et al., “Surface Modification of Low-Density Polyethylene Films by UV-Induced Graft Copolymerization and Its Relevance to Photolamination,” Langmuir 14(4):921-927 (1998), which is hereby incorporated by reference in its entirety).
In an alternative embodiment, hydrophobic surfaces are converted to hydrophilic ones using a hydrophilic coating (Zilio et al., “Universal Hydrophilic Coating of Thermoplastic Polymers Currently Used in Microfluidics,” Biomed Microdevice. 16(1):107-14 (2014), which is hereby incorporated by reference in its entirety). In another variation, the wettability of a device is spatially controlled using a photoreactive coating to generate the hydrophilic surface (Abate et al., “Photoreactive Coating for High-Contrast Spatial Patterning of Microfluidic Device Wettability,” Lab Chip 8(12):2157-60 (2008), which is hereby incorporated by reference in its entirety).
As described in U.S. Patent Application Publication No. 2015/0099642 to Barany et al., which is hereby incorporated by reference in its entirety, the surfaces of the solid support may also contain a layer of linker molecules that couple the oligonucleotides to the solid support, although it will be understood that the linker molecules are not required elements of the present invention. The linker molecules are preferably of sufficient length to permit polymers in a completed substrate to interact freely with molecules exposed to the substrate. The linker molecules should be 6-50 atoms long to provide sufficient exposure. Suitable linker molecules can be selected based upon their hydrophilic/hydrophobic properties. The linker molecules may be, for example, aryl acetylene, ethylene glycol oligomers containing 2-10 monomer units, diamines, diacids, amino acids, or combinations thereof.
The linker molecules can be attached to the substrate via carbon-carbon bonds using, for example, (poly)tri-fluorochloroethylene surfaces. The linker molecules may optionally be attached in an ordered array, i.e., as parts of the head groups in a polymerized monolayer. In alternative embodiments, the linker molecules are adsorbed to the surface of the substrate.
The device of the present invention can comprise various types of oligonucleotides depending on the application. In one embodiment of the present invention, the oligonucleotides of the device are capture oligonucleotide probes as described in U.S. Pat. Nos. 6,852,487 and 7,455,965 to Barany et al., which are hereby incorporated by reference in their entirety. Accordingly, the present invention also encompasses a method of capturing a plurality of target nucleotide sequence on a solid support.
Other suitable methods of solid-phase amplification that can be carried out using the device of the present invention are described in U.S. Pat. No. 6,017,738 to Morris et al., U.S. Pat. No. 7,741,463 to Gormley et al., U.S. Pat. No. 7,754,429 to Rigatti et al., and U.S. Pat. No. 6,355,431 to Chee et al., and U.S. Patent Publication No. 2009/0226975 to Sabot et al., U.S. Patent Publication No. 2001/0036632 to Yu et al., 2008/0108149 to Sundararajan et al., and U.S. Patent Publication No. 2005/0053980 to Gunderson et al., which are hereby incorporated by reference in their entirety. The device of the present invention is also suitable for carrying out other multiplex nucleic acid reactions including, without limitation, single-base or multi-base extension reactions, primer extension assays, solid-phase sequencing, solid phase oligonucleotide ligation assay, pair end reads, RNA sequencing, copy number analysis, ChIP sequencing, and others as described in U.S. Patent Application Publication No. 2010/0015626 to Oliphant et al., which is hereby incorporated by reference in its entirety.
As described in U.S. Patent Application Publication No. 2015/0099642 to Barany et al., which is hereby incorporated by reference in its entirety, one aspect of the present invention relates to methods of attaching oligonucleotides within micro-wells or micro-pores on a solid support. The first of these methods involves providing a solid support having a base surface, a top surface, and a plurality of side surfaces extending between the base and top surfaces. The base surface, top surface, and plurality of side surfaces collectively form a plurality of micro-wells or micro-pores on the solid support. A mask is applied to cover the base surface of the solid support and the masked device is exposed to an activating agent to activate the unmasked surfaces of the solid support, while the masked surfaces of the solid support are non-activated. The mask is removed from the solid support and the exposed solid support is contacted with a plurality of oligonucleotides under conditions effective for the oligonucleotides to attach to the activated surfaces of the solid support, but not to the non-activated surfaces of the solid support, thereby attaching oligonucleotides within micro-wells or micro-pores on a solid support.
As described in U.S. Patent Application Publication No. 2015/0099642 to Barany et al., which is hereby incorporated by reference in its entirety, in accordance with this aspect of the present invention, the solid support preferably comprises a polymer material. Suitable polymers include, without limitation, poly(methyl methacrylate), polycarbonates, polysulfones, elastomers, and polymeric organosilicones. The solid support having a base surface, top surface and plurality of side surfaces extending between the base and top surfaces is formed from a solid support having a planar surface where the planar surface has been treated to form base, top, and a plurality of side surfaces to generate micro-wells or micro-pores on a solid support. In one embodiment, the planar surface is subjected to hot embossing as described in U.S. Pat. No. 8,758,974 to Soper et al., which is hereby incorporated by reference in its entirety. This approach is preferred when the solid support comprises a polymeric material. In an alternative embodiment of this aspect of the present invention, the planar surface is subjected to photolithography to generate micro-wells or micro-pores on a solid support.
Methods of modifying surfaces of polymers for the attachment of biological molecules, including oligonucleotides is described in U.S. Pat. No. 8,758,974 to Soper et al., which is hereby incorporated by reference in its entirety. To achieve selective activation and attachment of oligonucleotides within micro-wells or micro-pores on a solid support, the plurality of patterned positions on the solid support are selectively masked and exposed to an activating agent, e.g., UV light. In one embodiment of this aspect of the present invention, the activating agent is actinic light. Preferably, exposure to actinic light is carried out in an oxidizing atmosphere. In many applications, ordinary air is suitable, although it is also possible to use an atmosphere with a higher or lower concentration of oxygen (or other oxidizing agent) to modify the patterning if desired. Other oxidizing agents known in the art may be used in lieu of, or in addition to, oxygen, for example SO2, NO2, or CNBr (see e.g., Kavc et al., “Surface Modification of Polyethylene by Photochemical Introduction of Sulfonic Acid Groups,” Chem. Mater. 12:1053-1059 (2000); Meyer et al, “Surface Modification of Polystyrene by Photoinitiated Introduction of Cyano Groups,” Macromol. Rapid Commun. 20:515-520 (1999), which are hereby incorporated by reference in their entirety). Actinic light exposure activates polymer surfaces, promoting photooxidation and generating carboxyl groups on the exposed surfaces. Suitable surfaces for actinic light activation include, without limitation, acrylate polymers (e.g., PMMA), aromatic polymers (e.g., polystyrene, phenoxy resins), polyamides, polysulfones, and copolymers.
Activation of the array surface using actinic light as the activating agent can be achieved via exposure to broadband ultraviolet light, narrow band UV lamps (e.g., 254 nm), or UV lasers at frequencies absorbed by the polymers being used. Alternatively, activation of the array surface can be achieved using an oxygen plasma as the activating agent. Cyclic olefin copolymer (COC) is a preferred polymer due to its extraordinarily low autofluorescence levels and its ability to generate a high density of functional groups following UV or oxygen plasma exposure.
As described in U.S. Pat. No. 8,758,974 to Soper et al., which is hereby incorporated by reference in its entirety, oligonucleotides, preferably, amine-terminated oligonucleotides are attached to the activated areas of the surface using methods well known in the art, e.g., click chemistry using ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) as a crosslinker and N-hydroxysuccinimide (NHS) an intermediate ester. However, other attachment chemistries can be used as well, such as disulfides, maleimides, or siloxanes. When forming an array containing a plurality of micro-wells or micro-pores, oligonucleotides are attached to activated side surfaces of the wells and bottom surfaces, if present, but not the masked top surfaces.
As described in U.S. Patent Application Publication No. 2015/0099642 to Barany et al., which is hereby incorporated by reference in its entirety, another method of forming arrays of oligonucleotides on a solid support involves providing a solid support having a planar substrate and a photosensitive layer over a surface of the substrate. The solid support is subjected to a photolithography process under conditions effective to form micro-wells or micro-pores on the solid support. The solid support is contacted with oligonucleotides under conditions effective for the oligonucleotides to attach to portions of the photosensitive layer which are either exposed or left unexposed by the photolithography process but not portions of the photosensitive layer which are left unexposed or exposed, respectively, thereby attaching oligonucleotides within micro-wells or micro-pores on the solid support.
Various methods of generating functional groups on photosensitive surfaces (i.e., SU-8 or one of its variants) to allow for the covalent attachment of oligonucleotides to the solid support are known in the art. Suitable functional groups include, without limitation, a carboxyl group, a carbonyl group, a hydroxyl group, an amino group, an epoxy group, and a silanol group.
As described in U.S. Patent Application Publication No. 2015/0099642 to Barany et al., which is hereby incorporated by reference in its entirety, SU-8 is a preferred surface material that comprises epoxide rings suitable for covalent attachment of oligonucleotides without additional activation or modification (See also Wang et al., “Surface Graft Polymerization of SU-8 for Bio-MEMS Applications,” J. Micromech. Microeng. 17:1371-1380 (2007), which is hereby incorporated by referenced in its entirety). In one embodiment, amine-terminated oligonucleotides can be added to the SU-8 surface using alkaline solutions (pH˜12) that hydrolyze surface epoxide groups and form secondary amines with the oligonucleotides carrying a primary amine. Alternatively, SU-8 micro-wells or micro-pores are treated with nitric acid to generate surface confined hydroxyl groups that are subsequently reacted with primary amine containing oligonucleotides (
Alternative attachment chemistries compatible with epoxy-based resists, such as SU-8, are also suitable for use to attach oligonucleotides to the internal surface of micro-wells or micro-pores. For example, in one embodiment a cross-linking reagent is used to modify the functional group present on the surface of the support. Suitable crosslinking reagents include, without limitation, glycine, glutaraldehyde, and aminopropyltriethoxysilane (APTES), as described in U.S. Patent Application Publication No. 2015/0099642 to Barany et al., which is hereby incorporated by reference in its entirety.
In one embodiment for immobilizing dendrimers on a solid support, multiple primers are attached to the solid surface through a series of branched oligodeoxyribonucleotides, known as bDNA. (Horn et al., “An Improved Divergent Synthesis of Comb-type Branched Oligodeoxyribonucleotides (bDNA) Containing Multiple Secondary Sequences,” Nucleic Acids Res. 25(23):4835-41 (1997), which is hereby incorporated by reference in its entirety). In this approach, bDNA contains one unique oligonucleotide, the primary sequence, covalently attached through a comb-like branch network to many identical copies of a different oligonucleotide, the secondary sequence. Multiple copies of a composite oligonucleotide, suitable for target amplification, are hybridized to, and then covalently cross-linked to the bDNA network. Suitable nucleotide analogues for interstrand cross-linking are provided below. Alternatively, strands may be linked using enzymatic processes such as a DNA ligase. The 5′ end of the composite oligonucleotide is designed to be complementary to the secondary sequences and suitable for crosslinking, while the 3′ end is suitable for use as a tag sequence for amplification of the desired target.
A versatile and creative embodiment for controlled assembly of dendrimer-like DNA uses Y-shaped DNA molecules created by hybridization. (Li et al., “Controlled Assembly of Dendrimer-like DNA,” Nat Mater. 3(1):38-42 (2004); Um et al., “Dendrimer-like DNA-based Fluorescence Nanobarcodes,” Nat Protoc. 1(2):995-1000 (2006); Campolongo et al., “DNA Nanomedicine: Engineering DNA as a Polymer for Therapeutic and Diagnostic Applications,” Adv Drug Deliv Rev. 62(6):606-16 (2010), which are hereby incorporated by reference in their entirety). Such molecules can be assembled by controlled hybridization, with ligation of smaller Y-shaped molecules to each other to create multi-armed dendrimer structures, and then made more permanent by crosslinking the DNA strands to each other. Use of a portion of terminal DNA molecules with an amino group, biotin group or other moiety at a 5′ or 3′ end such that it is suitable for covalent or non-covalent immobilization of the dendrimer complex to the solid support. Multiple copies of a composite oligonucleotide, suitable for target amplification, are hybridized to, and then covalently cross-linked or ligated to the bDNA network. The 5′ end of the composite oligonucleotide is designed to be complementary to the secondary sequences and suitable for crosslinking or ligation, while the 3′ end is suitable for use as a tag sequence for amplification of the desired target.
In another embodiment, branched DNA is synthesized from tripropargylated oligonucleotides by cycloaddition using “stepwise and double click” chemistry. (Xiong et al., “Construction and Assembly of Branched Y-shaped DNA: “click” Chemistry Performed on Dendronized 8-aza-7-deazaguanine Oligonucleotides,” Bioconjug Chem. 23(4):856-70 (2012), which is hereby incorporated by reference in its entirety). Dendronized oligonucleotides decorated with 7-tripropargylamine side chains carrying two terminal triple bonds are further functionalized with bis-azides to give derivatives with two terminal azido groups. Subsequently, the branched side chains with two azido groups or two triple bonds are combined with DNA-fragments providing the corresponding clickable function. Likewise, oligonucleotides comprising the commercially available azide, alkyne, or DBCO moiety may be used. These approaches yield branched (Y shaped) three-armed DNA. Annealing of branched DNA with a first set of complementary oligonucleotides yields supramolecular assemblies, which may be rendered heat stable by using the crosslinking approaches described herein. A second set of complementary composite oligonucleotides a hybridized to, and then covalently cross-linked or ligated to the supramolecular bDNA network. The 5′ end of the composite oligonucleotide is designed to be complementary to the first set of complementary oligonucleotides and suitable for crosslinking or ligation, while the 3′ end is suitable for use as a tag sequence for amplification of the desired target.
In another embodiment, the dendrimer is assembled directly on the solid support (Benters et al., “DNA Microarrays with PAMAM Dendritic Linker Systems,” Nucleic Acids Res. 30(2):E10 (2002), which is hereby incorporated by reference in its entirety). This approach uses pre-fabricated polyamidoamine (PAMAM) starburst dendrimers as mediator moieties between the solid support and the desired oligonucleotides suitable for use as a tag sequence for amplification of the desired target. Dendrimers containing 64 primary amino groups in their outer sphere are covalently attached to silylated glass supports and, subsequently, the dendritic macromolecules are modified with glutaric anhydride and activated with N-hydroxysuccinimide. The activated surface may now be decorated with amino-modified DNA-oligomers, yielding a highly stable surface with high loading density of the desired oligonucleotide primer.
In another embodiment, the primer may be covalently attached to the solid surface, another oligonucleotide, or to a dendrimer oligonucleotide using Dibenzocyclooctyl (DBCO) for copper-free click chemistry (to an azide); 5-Octadiynyl dU for click chemistry (to an azide); Amino Modifier C6 dT (for peptide linkage); or Azide, for click chemistry to an alkyne or DBCO. Oligonucleotides comprising modified bases suitable for crosslinking either to other oligonucleotides or to a solid support are commercially available, for example from IDT (Integrated DNA technologies, Coralville, Iowa 52241, USA).
In another embodiment, oligonucleotides are synthesized with a modified base containing a furan moiety. Upon exposure to visible light in the presence of methylene blue, this induces singlet oxygen formation, which triggers furan oxidation, and the resulting aldehyde then rapidly reacts with complementary A or C to form stable interstrand adducts. (Op de Beeck et al., “Sequence Specific DNA Cross-linking Triggered by Visible Light,” J Am Chem Soc. 134(26):10737-40 (2012), which is hereby incorporated by reference in its entirety).
Another approach to stabilize dendrimer structures is to use photo-crosslinking. (Rajendran et al., “Photo-cross-linking-assisted Thermal Stability of DNA Origami Structures and its Application for Higher-temperature Self-assembly,” J Am Chem Soc. 133(37):14488-91 (2011), which is hereby incorporated by reference in its entirety). In this approach 8-methoxypsoralen is used to crosslink pyrimidine bases to each other upon exposure to UV light.
In another embodiment, nucleotide analogs of abasic sites are used to facilitate interstrand crosslinking (Ghosh et al., “Synthesis of Cross-linked DNA Containing Oxidized Abasic Site Analogues,” J Org Chem. 79(13):5948-57 (2014), which is hereby incorporated by reference in its entirety).
In another embodiment, 4-vinyl substituted pyrimidine and 6-vinyl purine nucleotide analogs are used to form interstrand crosslinks (Nishimoto et al., “4-vinyl-substituted pyrimidine Nucleosides Exhibit the Efficient and Selective Formation of Interstrand Cross-links with RNA and Duplex DNA,” Nucleic Acids Res. 41(13):6774-81 (2013), which is hereby incorporated by reference in its entirety). These analogues include a 2-amino-6-vinylpurine derivative, for cross-linking with cytosine as well as 4-vinyl substituted pyrimidine derivatives, T-vinyl and U-vinyl.
As described in WO 2016/057832 to Barany et al., which is hereby incorporated by reference in its entirety, the oligonucleotide may be covalently attached to the solid surface using Dibenzocyclooctyl (DBCO) for copper-free click chemistry (to an azide); 5-Octadiynyl dU for click chemistry (to an azide); Amino Modifier C6 dT (for peptide linkage); or Azide, for click chemistry to an alkene or DBCO. Alternatively, the oligonucleotide may comprise a capture moiety such as a biotin group or a His-Tag, which would be captured by immobilized streptavidin or NTA matrix respectively present within the micro-wells or micro-pores on the solid support.
Alternative means of forming surfaces with covalently attached identical copies of the limited (short) RCA amplicon includes Sequoia amplification (WO2013/012440 to Barany et al., which is hereby incorporated by reference in its entirety) and wildfire amplification (Ma et al., “Isothermal Amplification Method for Next-Generation Sequencing,” Proc Natl Acad Sci USA 10(35):14320-3 (2013), which is hereby incorporated by reference in its entirety).
As described in WO 2015/188192 to Barany et al., which is hereby incorporated by reference in its entirety, the solid support can be made from a wide variety of materials. The substrate may be biological, nonbiological, organic, inorganic, or a combination of any of these, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, beads, containers, capillaries, pads, slices, films, plates, slides, discs, membranes, etc. The substrate may have any convenient shape, such as a disc, square, circle, etc. The substrate is preferably flat but may take on a variety of alternative surface configurations. For example, the substrate may contain raised or depressed regions on which the hybridization takes place. The substrate and its surface preferably form a rigid support on which to carry out sequencing reactions described herein.
Commercially available next generation sequencing solid support platforms used for template preparation can be utilized in the system and methods of the present invention. For example, the Illumina® Flow Cell, Life Technologies® IonSphere™ and emulsion PCR beads, and 454 emulsion PCR beads can be used in the system and methods of the present invention. Accordingly, the first solid support primer-specific portion of the circular chimeric single stranded nucleic acid constructs is designed to be the same as the primers immobilized on a commercially available NGS solid support. Therefore, the extension products containing the complement of the first solid support primer-specific portion are capable of hybridizing to primers on the NGS solid support surface.
For best sequencing signal, especially if amplifying multiple products in a micro-pore or bead, it is desirable to amplify products such that most of the immobilized primers are extended, converting them to target-comprising strands suitable for sequencing.
Sequencing of the immobilized extension products can be achieved using sequence-by-synthesis as described and depicted herein. Sequence-by-synthesis includes fluorescence-based sequencing-by-synthesis and ion-based sequencing-by-synthesis. Other suitable sequencing methods can also be employed, including, for example and without limitation, fluorescent primer hybridization, molecular beacon hybridization, primer extension, exonuclease-based sequencing, ligase detection reaction, ligase chain reaction, pyrosequencing, fluorescence-based sequencing-by-ligation, nanopore and nanotube based sequencing, and ion-based sequencing-by-ligation.
As described more fully in WO 2016/154337 to Barany et al., which is hereby incorporated by reference in its entirety, suitable capture molecules and methods for immobilizing target nucleic acid molecules on the solid support are described supra. Similarly, methods of generating immobilized extension products that are complementary to the target nucleic acid molecule using solid phase amplification are also described supra.
In accordance with this aspect of the present invention, the immobilized target nucleic acid molecule or immobilized extension product thereof is subject to a nucleotide extension reaction process. The nucleotide extension reaction mixture comprises a collection of nucleotide triphosphates where each type of nucleotide triphosphate in the collection has (i) a different cleavable fluorescently labeled group, and (ii) a cleavable blocking moiety that inhibits addition of a subsequent nucleotide triphosphate.
The blocking moiety of the nucleotide triphosphate may directly block the addition of a subsequent nucleotide triphosphate at its 3′OH group. In this embodiment, the blocking moiety is appended to the nucleoside triphosphate at the 2′-O of a ribose, or the 3′-O of a deoxyribose. These nucleotide triphosphates are the same as or analogous to fluorescent sequencing-by-synthesis (Ju et al., “Four-color DNA Sequencing by Synthesis Using Cleavable Fluorescent Nucleotide Reversible Terminators,” Proc Natl Acad Sci USA 103(52):19635-40 (2006), which is hereby incorporated by reference in its entirety). In the case of 3′-O blocking groups, there are several well-demonstrated examples in the literature such as but not limited to amino, azidomethyl, and cyanoethyl groups. The specific nature of the group should be chosen for a combination of efficiency of enzymatic incorporation and ease of removal during the deblocking step. Removal of the blocking group is specific to the chemical nature of the blocking group but examples would be the use of mild aqueous reagents (i.e., reducing agents) at temperatures that preserve the primer-template duplex and do not cause loss of signal due to melting of the primer-template duplex.
Alternatively, the blocking moiety of the nucleotide triphosphate reversibly inhibits the addition of a subsequent nucleotide triphosphate at its 3′OH group. These blocking moieties can be appended to a nucleotide triphosphate at the C5 or C7 position of the nucleoside, i.e., the pyrimidine or purine, respectively. These nucleotide triphosphates are the same as or similar to Lightning Terminators™ (LaserGen, Inc.) (Gardner et al., “Rapid Incorporation Kinetics and Improved Fidelity of a Novel Class of 3′OH Unblocked Reversible Terminators,” Nucleic Acids Research 40(15):7404-15 (May 2012) and Litosh et al., “Improved Nucleotide Selectivity and Termination of 3′-OH Unblocked Reversible Terminators by Molecular Tuning of 2 nitrobenzyl Alkylated HOMedU Triphosphates,” Nucleic Acids Research 39(6):e39 (2011), which are hereby incorporated by reference in their entirety) and Virtual Terminator™ (Helicos BioSciences) (Bowers et al., “Virtual Terminator Nucleotides for Next-Generation DNA Sequencing,” Nat. Methods 6:593-595 (2003), U.S. Pat. No. 8,071,755 to Efcavitch et al, U.S. Pat. No. 8,114,973 to Siddiqi et al, WO 2008/0169077 to Siddiqi et al, which are hereby incorporated by reference in their entirety). Chemical moieties which interfere with incorporation of dNTPs by a template dependent DNA polymerase that utilize steric bulk or charged inhibition or combinations of both can be used. Examples of inhibitory moieties are dipeptides of Glu-Glu or Asp-Asp.
In all these embodiments, a gene-specific primer may be used to initiate sequencing-by-synthesis to determine the unique sequence of the target. In one embodiment, the upstream locus-specific primers used in the initial nested amplification may double as sequencing primers. Since these primers are unblocked with RNaseH2 only when bound to the target, essentially eliminating potential false-reads from primer binding incorrectly.
Alternatively, the locus-specific primers are designed to comprise of variable regions. Individual targets will contain distinct variable regions and are then sequenced by using individual primers. In one embodiment, a first set of 8-16 sequencing primers comprises a common 5′ sequence (16 bases), and variable 3′ sequences (8 bases). Or, a second set of 64-256 sequencing primers comprises a common 5′ sequence (8 bases), a variable middle sequence (8 bases, 8-16 variants) and hyper-variable 3′ sequences (8 bases, 64-256 variants). One approach is to use split & pool synthesis strategies. By way of example, synthesis of a family of 16 variant primers would comprise synthesis of the locus-specific 3′ region, splitting into 4 aliquots, each getting an additional four bases, pooling, and splitting again into 4 aliquots, each getting an additional four bases, and then pooling and finishing synthesis with 16 bases of common sequence on the 5′ end. Consider the initial 4 bases on the 3′ side being GTCA, ACTG, TGAC, and CAGT, the next four bases being GCTA, ATCG, TAGC, and CGAT, followed by 16 bases on the 5′ side. Then a set of 16 sequencing primers could be used to sequence each amplicon uniquely, while minimizing mis-priming from one primer binding to a mismatched complement.
The cartridge design of
In an alternative embodiment using 48 double-columns and 48 double-rows equaling 2,304 subdivisions, each subdivision comprising 11,040 micro-pores, with 529,920 micro-pores per double-column. Initial multiplexed amplification of the sample for 10 cycles of PCR, provides a maximum of 1,024 copies of each original pathogen in a well or Initial Reaction Chamber. Distribute initial multiplexed products into 48 wells or Primary PCR Reaction Chambers, mixed with locus-specific primers, buffer, and polymerase into the Primary PCR Reaction Chambers, for example by using acoustic droplet ejection as illustrated in
In an alternative embodiment, low-abundance mutations are identified and enumerated using 48 double-columns and 48 double-rows equaling 2,304 subdivisions, each subdivision comprising 11,040 micro-pores, with 529,920 micro-pores per double-column. Distribute initial sample into 48 wells or Primary PCR Reaction Chambers, mixed with locus-specific primers, buffer, and polymerase into 48 Primary PCR Reaction Chamber, for example by using acoustic droplet ejection as illustrated in
The design illustrated in
During manufacture of the cartridge, micro-pores are pre-filled with a single universal primer, which is immobilized, and micro-pores are dried. Since all subdivisions contain the identical primer, they may be added through the columns, or by other means. During use of the cartridge, reactions are fluidically moved up the cartridge, and eventually up the columns of micro-wells or micro-pores, where each column is isolated from its neighbor column. In this illustrative example, showing 4 each of the planned 48 columns 64 rows equaling 3,072 subdivisions, each subdivision comprising 2,760 micro-pores, for a total of 8,478,720 micro-pores in the array, the initial plasma DNA (adjusted to 2,000 genome equivalents) is combined with buffer, enzymes, fragment identifier primers, equally split, and fluidically moved into the set of diamond chambers is divided into 48 Primary PCR Reaction Chambers, with average distribution of 40 copies of each locus per Primary PCR Reaction Chamber, with different SNPs. Optionally, primers containing an RNA base and 3′ blocking group are unblocked with RNaseH2 only when bound to the correct target, providing additional specificity and avoiding false products. Perform 3 cycles of fragment identifier PCR for both strands, each strand covering slightly different sequences. Yields 4 copies of top strand, and 4 copies of bottom strand. Remove universal primer sequence from product with UDG/APE1 to generate single-stranded tails on both sides of the PCR products, which facilitates hybridization to immobilized primer in micro-pore. If needed, fresh PCR reagents are added, mixed with the PCR products of each Primary PCR Reaction Chamber, and distributed into the Mixing Chambers and then into the micro-pores of each column. PCR amplify one or more products in each micro-pore using nested target-specific primer and universal primer and melt off non-anchored strand. Add either target-specific, or universal primers with unique tag-specific portions as sequencing primers. Perform sequencing-by-synthesis. Generate about 50 bases of sequence information, plus 10 bases of unique fragment identifier barcode, for accurate enumeration of each SNP and chromosomal copy number, with verification on both strands.
In an alternative embodiment, for identifying chromosomal copy changes in NIPT, using 48 double-columns and 48 double-rows equaling 2,304 subdivisions, each subdivision comprising 11,040 micro-pores, with 529,920 micro-pores per double-column. Distribute initial sample into 48 wells or Primary PCR Reaction Chambers. Adjust DNA in plasma/sample to 2,000 genome equivalents. Distribute initial sample mixed with locus-specific primers, buffer, and polymerase into 48 wells or Primary PCR Reaction Chambers, for example by using acoustic droplet ejection as illustrated in
The ability to accurately enumerate copy number in a clinical sample has additional uses as well. In the field of NIPT, there may be an opportunity to detect de novo Duchenne's muscular dystrophy (DMD). This disease may arise sporadically due to deletion of a portion of the DMD gene. Coverage of both SNPs and all exons across the DMD would allow for accurate assessment of copy loss.
Another embodiment of the ability to accurately enumerate both copy number and SNPs would be to identify LOH or gene amplification, initially in circulating tumor cells (CTC's), but ultimately in cfDNA as well. This approach would be facilitated by determining the haplotype of the diploid genome in normal cells for that patient, which may be accomplished by standard approaches from DNA isolated from the buffy coat fraction (polymorphonuclear leukocytes, PMN's). Sufficient DNA would be required to achieve statistical significance, but briefly if there is a consistent undercount or over count of all the SNPs on a given chromosomal arm (i.e. 8p, often lost in cancers; or 20q, often gained in cancers) then that would suggest loss or gain of that arm respectively in the clinical sample. Depending on the percent of tumor derived cfDNA in the plasma sample, this technique may be sensitive enough for detection of cancer (i.e. when trying to identify LOH in cfDNA), and it may assist in guiding treatment decisions, or monitoring efficacy of therapy (i.e. when scoring for copy changes directly from CTC's).
The cartridge and valve setup of
In an alternative embodiment, low-abundance methylation and mutations are identified and enumerated using 48 double-columns and 48 double-rows equaling 2,304 subdivisions, each subdivision comprising 11,040 micro-pores, with 529,920 micro-pores per double-column. Divide initial plasma sample in half, and then distribute half into 48 wells or Primary PCR Reaction Chambers, mixed with locus-specific primers, buffer, and polymerase into 48 subdivisions, for example by using acoustic droplet ejection as illustrated in
The cartridge and valve setup of
The assay described below would use a cartridge with 24×16=384 (or optional 768) subdivisions for 9,216 micro-well or micro-pore array format, with 24 micro-wells or micro-pores per subdivision, and 384 micro-wells or micro-pores per column (using pre-spotted array): Please see
The assay may be designed to detect and quantify 384, 768, or 1,536 potential targets. Preparation of the cartridge would require spotting 24× of either 16, 32, or 64 nested PCR primer pairs on the front side of the array, with adding UniTaq or Universal Tag primer and target-specific probe sets at right angles and drying them down before cartridge assembly.
1. Initial multiplexed amplification of the sample—384, 768, or 1536 potential targets. Perform 9 cycles of multiplexed PCR in the Initial Reaction chamber, yielding a maximum of 512 copies of each original pathogen. If needed, use “tandem” PCR primers. Also, all PCR primers may include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
2. Distribute initial multiplexed products into 24 Primary PCR Reaction Chambers. Average distribution in each Primary PCR Reaction Chamber is 20 copies of each original pathogen target. Perform 5 cycles of nested PCR using primers with UniTaq tails, in groups of 16, 32, or 64 primer sets, for a maximum of 640 copies of each original pathogen.
3. Distribute products of each Primary PCR Reaction Chamber into 384 micro-wells or micro-pores. On average, each subdivision (comprising 24 micro-wells or micro-pores) will get 40 copies of each original pathogen, with a given well getting one or two copies of original pathogen. If pathogen present in higher numbers, each subdivision will get additional copies. PCR amplify 1, 2, or 4 potential products in each well using the UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers. Poisson distribution in 24 micro-wells or micro-pores (per subdivision) will enumerate pathogen-specific targets initially present at low abundance, while Ct values across 24 micro-wells or micro-pores (per subdivision) will provide approximate copy information for pathogen-specific targets initially present at high abundance.
Note 1: The success of this assay format depends on there being no primer dimers formed by the UniTaq primers, especially when using nested primers. Using 3′-blocked UniTaq primers and RNaseH2 to unblock at an RNA base would solve this problem (see
Note 2: An additional approach to avoid target-independent signal from primer dimers is to use nested primers that comprise partial target sequence in the tag region and amplify a complementary region within the target using a strand-displacing polymerase that lacks the 5′-3′ nuclease activity. After the UniTaq amplification step, and denaturation of the double-stranded product, the labeled product forms a cloverleaf structure, bringing an RNA base in the probe into a double-stranded form and suitable for liberating the fluorescent group with RNaseH2 (See
Note 3: For RNA viruses, an initial Reverse-transcriptase step would be included—or one can use Tth DNA polymerase and Mn2+ in the amplification buffer for a single-step RT-PCR. Note also that the sample may be split, and one aliquot is used to amplify potential RNA targets, say for 10-cycles, while the second is used to amplify potential low-level bacterial targets, for example for 20 cycles. The two separate PCR amplification products are then mixed, diluted into PCR buffer, and distributed into the 24 subdivisions for the nested PCR reactions.
Note 4: One advantage of using the UniTaq primers is they may be placed very close to each other such that multiple nested products may be generated off a single initial target amplicon. This allows primer design with 2, 3, or 4 initial targets for each pathogen, followed by 2, 3, or 4 nested primer sets within each target fragment. A pathogen would then only be called positive if a minimum of 2 or 3 of the 4 to 16 possible signals are observed. Another advantage of this approach is it would limit the number of PCR primers in the initial multiplexed reaction. A further advantage is that primers can be designed such that those signals are displayed in different subdivisions to mitigate any target-independent (false) signals.
Prophetic Example 2—Use of PCR-PCR-Taqman™ or PCR-PCR Unitaq Detection for Unknown Pathogen Identification and QuantificationThe assay described below would use a cartridge with 48×48=2,304 subdivisions for 221, 1846 micro-well array format, with 96 micro-wells per subdivision, and 4,608 micro-wells per column (acoustic droplet ejection into microtiter array plate): Please see
The assay may be designed to detect and quantify 576, or 1,152 potential targets. Preparation of the microtiter plate would require spotting UniTaq or Universal Tag primer and target-specific probe sets and drying them down before use of microtiter plate.
1. Initial multiplexed amplification of the sample—576, or 1,152 potential targets. Perform 10 cycles of multiplexed PCR in a well or Initial Reaction Chamber, maximum of 1,024 copies of each original pathogen. If needed, use “tandem” PCR primers. Also, all PCR primers may include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
2. Distribute initial multiplexed products into 48 wells or Primary PCR Reaction Chambers. Average distribution in each well or Primary PCR Reaction Chamber is 20 copies of each original pathogen target. Perform 3-4 cycles of nested PCR using primers with UniTaq tails, in groups of 24, or 48 primer sets, for a maximum of 160-320 copies of each original pathogen.
3. Distribute products of each well or Primary PCR Reaction Chamber into 2 or 4 sets of 24 or 12 subdivisions, respectively, containing 96 micro-wells. When using 2 sets, the second set is a 100/1 dilution of the first. When using 4 sets, each set is a 20/1 dilution of the previous set. This allows coverage of pathogens present across many orders of magnitude. On average, each initial subdivision will get 12 copies of each original pathogen, with a given micro-well getting one or zero copies of original pathogen. If pathogen is present in higher numbers, each subdivision will get additional copies. PCR amplify 1, 2, or 4 potential products in each micro-well using the pre-spotted UniTaq primer sets and determine Ct value in each micro-well of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers. Poisson distribution in 96 micro-wells across 2 or 4 dilution sets will provide some degree of enumeration for very low copy pathogen, as well as higher copy pathogen in sample.
See also, notes 1-4 in Example 1 above.
Prophetic Example 3—Use of PCR-LDR-Taqman™, PCR-LDR Unitaq, or PCR-LDR-Split UniTaq (UniSpTq) Detection for Unknown Pathogen Identification and QuantificationThe assay described below would use a cartridge with 24×16=384 (or optional 768) subdivisions for 9,216 micro-well or micro-pore array format, with 24 micro-wells or micro-pores per subdivision, and 384 micro-wells or micro-pores per column (using pre-spotted array): Please see
The assay may be designed to detect and quantify 384, 768, or 1,536 potential targets. Preparation of the cartridge would require spotting 24× of either 16, 32, or 64 LDR primer pairs on the front side of the array, with adding UniTaq or Universal Tag primer and target-specific probe sets at right angles and drying them down before cartridge assembly.
1. Initial multiplexed amplification of the sample—384, 768, or 1536 potential targets. Perform 30 cycles of PCR in the Initial Reaction Chamber, to provide maximum amplification of each original pathogen. If needed, use “tandem” PCR primers. Also, all PCR primers should include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
2. Distribute initial multiplexed products into 24 Primary LDR Reaction Chambers, while diluting 10-fold. Average distribution in each Primary LDR Reaction Chamber will be millions of copies of each original pathogen target. Perform 20 cycles of LDR using allele-specific primers with UniTaq tails, in groups of 16, 32, or 64 primer sets.
3. Distribute LDR products of each Primary LDR Reaction Chamber into 384 micro-pores. PCR amplify 1, 2, or 4 potential products in each well using the UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers. Ct values across 24 micro-wells or micro-pores (per subdivision) provide approximate copy information for pathogen-specific targets initially present at high abundance.
Note 1: The success of this assay format depends on there being no primer dimers formed by the UniTaq primers, e.g. with the downstream LDR primers. This problem has been solved as follows: The initial PCR reaction includes UDG to destroy any accidental carryover contamination in the original sample, and the PCR products incorporate dUTP. After LDR, the UniTaq master mix contains UDG, and will destroy any of the PCR products, such that the only amplification can come off the LDR product. (See also,
Note 2: When using the UniTaq primers for the last amplification step, it may be performed using either a simple probe design (
Note 3: For RNA viruses, an initial Reverse-transcriptase step would be included—or one can use Tth DNA polymerase and Mn2+ in the amplification buffer for a single-step RT-PCR. Note also that the sample may be split, and one aliquot is used to amplify potential RNA targets, say for 30-cycles, while the second is used to amplify potential low-level bacterial targets, for example for 40 cycles. The two separate PCR amplification products are then mixed, diluted into LDR buffer, and distributed into the 24 Secondary LDR Reaction Chamber for the LDR reactions.
Note 4: One advantage of using LDR primers is they may be placed very close to each other such that multiple, even overlapping LDR products may be generated off a single initial target amplicon. This allows primer design with 2, 3, or 4 initial targets for each pathogen, followed by 2, 3, or 4 LDR primer sets within each target fragment. A pathogen would then only be called positive if a minimum of 2 or 3 of the 4 to 16 possible signals are observed. Another advantage of this approach is it would limit the number of PCR primers in the initial multiplexed reaction. A further advantage is that primers can be designed such that those signals are displayed in different subdivisions to mitigate any target-independent (false) signals.
Prophetic Example 4—Use of PCR-PCR-qLDR Detection or PCR-qLDR Detection With Either Universal or Target-Specific Probes, (e.g. UniLDq or TsLDq) for Unknown Pathogen Identification and QuantificationThe assay described below would use a cartridge with 24×16=384 (or optional 768) subdivisions for 9,216 micro-well or micro-pore array format, with 24 micro-wells or micro-pores per subdivision, and 384 micro-wells or micro-pores per column (using pre-spotted array): Please see
The assay may be designed to detect and quantify 384, 768, or 1,536 potential targets. Preparation of the cartridge would require spotting 24× of either 16, 32, or 64 nested PCR primer pairs on the front side of the array, with adding qLDR primer and probe sets at right angles, and drying them down before cartridge assembly.
1. Initial multiplexed amplification of the sample—384, 768, or 1536 potential targets. Perform 10-15 cycles of PCR in the Initial Reaction Chamber, to provide 1,000 to 32,000-fold amplification of each original pathogen target. If needed, use “tandem” PCR primers. Also, all PCR primers should include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
2. Distribute initial multiplexed products into 24 Primary PCR Reaction Chambers, while diluting 10-fold. Average distribution in each Primary PCR Reaction Chamber will be 4 to 130 copies of each original pathogen target. Perform 20-30 cycles of PCR using either a subset of the above primers, or nested primers, in groups of 16, 32, or 64 primer sets. Also, all PCR primers should include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
3. Distribute PCR products of each Primary PCR Reaction Chamber into 384 micro-wells or micro-pores. iLDR (“i” is for isothermal) amplify 1, 2, or 4 potential products in each well using the primer sets as described below, and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers.
Alternatively, for Unknown Bacterial Pathogen Identification Directly from Blood (Using PCR-qLDR Detection):
1. Distribute initial sample into 24 Primary PCR Reaction Chambers. Initial multiplexed amplification of the sample—32, 64, or 128 potential targets. Perform 30-40 cycles of multiplexed PCR, to provide billions of copies of each original target, if present. Use “tandem” or more PCR primer sets. Also, all PCR primers include identical 5′ tail sequences, preferably 10-12 bases to suppress amplification of primer dimers.
2. Distribute PCR products of each Primary PCR Reaction Chamber into 384 micro-pores. iLDR (i is for isothermal) amplify 1, 2, or 4 potential products in each well using the primer sets as described below and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers.
Note 1: As an alternative to using UniTaq to generate fluorescent signal, a new approach is introduced; termed “iLDR” (i for isothermal), see
Note 2: The second version of iLDR uses probes that are sequence-specific. Here, the LDR primers contain one tag sequence (Bi′), and one sequence complementary to the ligation junction region (tj′). In the presence of probe (F1-r-pathogen sequence-Bi-Q), and after the denaturation step, as the temperature decreases, 2 double-stranded stems form between pathogen-specific sequences (ti,tj & ti′,tj′), and Bi & Bi′. This renders the ribose base in the pathogen sequence double-stranded, enabling RNaseH2 to liberate the fluorescent group and generate signal. The cleaved probe dissociates from the product and new probe can hybridize to generate additional signal. Unligated LDR primers would not form both stems, and thus RNaseH2 would not liberate signal. As above, the amount of signal generated is a function of how many probes are cleaved during each hybridization step to the cumulative LDR product formed in the previous LDR steps.
Note 3: For RNA viruses, an initial Reverse-transcriptase step would be included—or one can use Tth DNA polymerase and Mn2+ in the amplification buffer for a single-step RT-PCR. Note also that the sample may be split, and one aliquot is used to amplify potential RNA targets, say for 30-cycles, while the second is used to amplify potential low-level bacterial targets, for example for 40 cycles. The two separate PCR amplification products are then mixed, diluted into LDR buffer, and distributed into the 24 Secondary LDR Reaction Chambers for the LDR reactions.
Note 4: One advantage of using LDR primers is they may be placed very close to each other such that multiple, even overlapping LDR products may be generated off a single initial target amplicon. This allows primer design with 2, 3, or 4 initial targets for each pathogen, followed by 2, 3, or 4 LDR primer sets within each target fragment. A pathogen would then only be called positive if a minimum of 2 or 3 of the 4 to 16 possible signals are observed. Another advantage of this approach is it would limit the number of PCR primers in the initial multiplexed reaction. A further advantage is that primers can be designed such that those signals are displayed in different subdivisions to mitigate any target-independent (false) signals.
Prophetic Example 5—Use of PCR-PCR-Taqman™ or PCR-PCR Unitaq Detection for Unknown Pathogen Identification and Quantification Directly from BloodThe assay described below would use a cartridge with 24×16=384 (or optional 768) subdivisions for 9,216 micro-well or micro-pore array format, with 24 micro-wells or micro-pores per subdivision, and 384 micro-wells or micro-pores per column (using pre-spotted array): Please see
The assay may be designed to detect and quantify 32, 64, or 128 potential targets. Preparation of the cartridge would require spotting 16, 32, or 64 nested PCR primer pairs on the front side of the array, with adding UniTaq or Universal Tag and target-specific probe and primer sets at right angles and drying them down before cartridge assembly.
1. Distribute initial sample into 24 Primary PCR Reaction Chambers. Initial multiplexed amplification of the sample—32, 64, or 128 potential targets. Perform 20 cycles of multiplexed PCR, maximum of 1,000,000 copies of each original target, if present. Use “tandem” or more PCR primer sets. Also, all PCR primers include identical 5′ tail sequences, preferably 10-12 bases to suppress amplification of primer dimers.
2. Perform 10 cycles of nested PCR in Secondary PCR Reaction Chambers using primers with UniTaq tails, in groups of 16, 32, or 64 primer sets. Primers are unblocked with RNaseH2 only when bound to correct target.
3. Distribute PCR products of each Secondary PCR Reaction Chamber into 384 micro-pores. Universal or UniTaq primers in each row will amplify only those products from each column with the correct tags. Pre-amplification of target and use of tails to prevent primer dimer formation will allow identification of bacterial pathogens at the single cell level.
Note 1: The success of this assay format depends on there being no primer dimers formed by the UniTaq primers, e.g. with the nested primers. Using 3′-blocked UniTaq primers and RNaseH2 to unblock at an RNA base would solve this problem. The same 3′ block/RNase trick may also be used on the nested primer set; however, there is a slight risk such primers would be less effective since sequence drift of the pathogen may prevent the primers from amplifying that particular target.
Note 2: One advantage of using the UniTaq primers is they may be placed very close to each other such that multiple nested products may be generated off a single initial target amplicon. This allows primer design with 2, 3, or 4 initial targets for each pathogen, followed by 2, 3, or 4 nested primer sets within each target fragment. A pathogen would then only be called positive if a minimum of 2 or 3 of the 4 to 16 possible signals are observed.
Prophetic Example 6—Use of PCR-PCR-Taqman™ or PCR-PCR Unitaq Detection for Unknown Pathogen Identification and Quantification Directly From BloodThe assay described below would use a cartridge with 48×48=2,304 subdivisions for 221, 1846 micro-well array format, with 96 micro-wells per subdivision, and 4,608 micro-wells per column (acoustic droplet ejection into microtiter array plate): Please see
The assay may be designed to detect and quantify 48, 96, or 192 potential targets. Preparation of the microtiter plate would require spotting UniTaq or Universal Tag primer and target-specific probe sets, and drying them down before use of microtiter plate.
1. Distribute initial sample into 48 wells or Primary PCR Reaction Chambers. Initial multiplexed amplification of the sample—48, 96, or 192 potential targets. Perform 9 cycles of multiplexed PCR, maximum of 512 copies of each original pathogen, if present. Use “tandem” or more PCR primer sets. Also, all PCR primers include identical 5′ tail sequences, preferably 10-12 bases to suppress amplification of primer dimers.
2. Distribute products of each well or Primary PCR Reaction Chamber into 48 subdivisions respectively containing 96 micro-wells. The subdivisions have been pre-spotted with appropriate nested target-specific primers, UniTaq primers, and/or probes; (see
See notes 1-2 for Example 5 above.
Prophetic Example 7—Use of PCR-LDR-Taqman™ or PCR-LDR Unitaq Detection for Low Abundance Mutation and/or CpG Methylation Identification and Quantification Directly from PlasmaThe assay described below would use a cartridge with 24×16=384 (or optional 768) subdivisions for 9,216 micro-well or micro-pore array format, with 24 micro-wells or micro-pores per subdivision, and 384 micro-wells or micro-pores per column (using pre-spotted array): Please see
The assay may be designed to detect and quantify 64, or 128 potential targets, allowing for multiple mutations to be scored by a single fluorescent color. Preparation of the cartridge would require spotting 16, 32, or 64 nested PCR primer pairs on the front side of the array, with adding UniTaq or Universal Tag and target-specific probe and primer sets at right angles, and drying them down before cartridge assembly.
1. Distribute initial sample into 24 Primary PCR Reaction Chambers. Highest level of DNA in plasma=10,000 genome equivalents. On average, 400 copies of each target per Primary PCR Reaction Chamber, with at most 1 mutation. Perform 10-40 cycles of locus-specific PCR with blocking PNA or LNA to reduce amplification of wild-type DNA. Optional: Use dUTP during PCR reaction (and pre-treat with UDG to avoid carryover contamination of initial sample. Also, all downstream PCR primers should include identical 5′ tail sequences, preferably 8-11 bases to suppress amplification of primer dimers.
2. Dilute products of each Primary PCR Reaction Chamber with LDR primers and buffers, and distribute products into Secondary LDR Reaction Chambers. Perform 20 cycles of LDR using allele-specific primers with UniTaq tails, in groups of 16, 32, or 64 primer sets. LDR primers for different mutations of the same gene may be designed to give the same signal in the same subdivision. LDR reactions may be performed in the same reaction chamber, or in 2 separate reaction chambers, and then re-combined.
3. Add UniTaq master mix and UDG and distribute products of each Secondary LDR Reaction Chamber into 384 micro-pores. PCR amplify 1, 2, or 4 potential products in each well using the UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers.
Note 1. This design provides the option of using the identical LDR primer sets across the board, or printing different LDR primer sets, which then combine with aliquots of the PCR reaction, and then the products are combined again before distributing onto the micro-pores.
Note 2. Another layer of selectivity can be incorporated into the method by including a 3′ blocking group, and an RNA base, in the upstream primer. Upon target-specific hybridization, RNase H2 removes the RNA base to liberate a 3′OH group which is a few bases upstream of the mutation, and suitable for polymerase extension. The blocking LNA or PNA probe comprising wild-type sequence that partially overlaps with the upstream PCR primer will preferentially compete in binding to wild-type sequence over the upstream primer, but not as much to mutant DNA, and thus suppresses amplification of wild-type DNA during each round of PCR.
Note 3. Likewise, further selectivity can be incorporated into the method by including a 3′ blocking group, and an RNA base, in the downstream primer, which is removed by RNase H2 upon target-specific hybridization. Further, the identical 5′ tails can be extended, to about 24-30 bases. The sequence would allow addition of a “universal” primer (also including a 3′ blocking group, and an RNA base), which would be present at higher concentration than the locus-specific primers for the initial PCR amplification step. The universal primer would facilitate amplification of all PCR products during the multiplexed amplification.
Note 4. Alternatively, to minimize dropout of fragments during multiplexed PCR, an initial “pre-amplification” multiplexed PCR is performed for 8-20 cycles in an initial reaction chamber. These products are then distributed into the 24 Primary PCR Reaction Chambers. In one variation, each of the 24 primary reaction chambers contains from 1-4 PCR primer sets with PNA or LNA to suppress amplification of wild-type sequence, and single or multiplexed PCR is performed for an additional 10-30 cycles to enable amplification of 1-4 different fragments containing potential mutations in a single primary reaction chamber. In another variation, 6 sets of 4 primary reaction chambers contains from 4-16 PCR primer sets with PNA or LNA to suppress amplification of wild-type sequence, and multiplexed PCR is performed for an additional 10-30 cycles to enable amplification of 4-16 different fragments containing potential mutations in a single primary reaction chamber.
Note 5. This design also allows combining with methylation detection.
For Identification and Quantification of Low Abundance CpG Methylation in Plasma (when Combined with Mutation; Using Bisulfite-PCR-LDR-Taqman™, or Bisulfite-PCR-LDR-Unitaq Detection. See
1. Digest sample with Bsh1236I in the Initial Reaction Chamber. Treat with Bisulfite. Re-purify DNA strands.
2. Distribute bisulfate treated sample into 24 Primary PCR Reaction Chambers. Highest level of DNA in plasma after RE cleavage=200 genome equivalents. Perform 0-40 cycles of locus-specific PCR with optional blocking PNA or LNA to reduce amplification of wild-type DNA, if needed. Use dUTP during PCR reaction. Also, all downstream PCR primers should include identical 5′ tail sequences, preferably 8-11 bases to suppress amplification of primer dimers.
2. Dilute products of each Primary PCR Reaction Chamber with LDR primers and buffers and distribute products into Secondary LDR Reaction Chambers. Perform 20 cycles of LDR using methyl-specific primers with UniTaq tails, in groups of 16, 32, or 64 primer sets. LDR primers for different methylation regions, i.e. top and bottom strand of the same promoter region may be designed to give the same signal in the same subdivision. LDR reactions may be performed in the same reaction chamber, or in 2 separate reaction chambers, and then re-combined.
3. Add UniTaq master mix and UDG and distribute products of each Secondary LDR Reaction Chambers into 384 micro-pores. PCR amplify 1, 2, or 4 potential products in each well using the UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers.
Note 1. This design provides the option of using the identical LDR primer sets across the board, or printing different LDR primer sets, which then combine with aliquots of the PCR reaction, and then the products are combined again before distributing onto the micro-pores.
Note 2. Another layer of selectivity can be incorporated into the method by including a 3′ blocking group, and an RNA base, in the upstream primer. Upon target-specific hybridization, RNase H2 removes the RNA base to liberate a 3′OH group which is a few bases upstream of the mutation, and suitable for polymerase extension. The blocking LNA or PNA probe comprising wild-type sequence that partially overlaps with the upstream PCR primer will preferentially compete in binding to wild-type sequence over the upstream primer, but not as much to mutant DNA, and thus suppresses amplification of wild-type DNA during each round of PCR.
Note 3. Likewise, further selectivity can be incorporated into the method by including a 3′ blocking group, and an RNA base, in the downstream primer, which is removed by RNase H2 upon target-specific hybridization. Further, the identical 5′ tails can be extended, to about 24-30 bases. The sequence would allow addition of a “universal” primer (also including a 3′ blocking group, and an RNA base), which would be present at higher concentration than the locus-specific primers for the initial PCR amplification step. The universal primer would facilitate amplification of all PCR products during the multiplexed amplification.
Note 4. In another embodiment, to minimize dropout of fragments during multiplexed PCR, an initial “pre-amplification” multiplexed PCR is performed for 8-20 cycles in the initial reaction chamber. These products are then distributed into the 24 Primary PCR Reaction Chambers. In one variation, each of the 24 primary reaction chambers contains from 1-4 PCR primer sets, and single or multiplexed PCR is performed for an additional 10-30 cycles to enable amplification of 1-4 different fragments containing potential methylations in a single primary reaction chamber. In another variation, 6 sets of 4 primary reaction chambers contains from 4-16 PCR primer sets, and multiplexed PCR is performed for an additional 10-30 cycles to enable amplification of 4-16 different fragments containing potential methylations in a single primary reaction chamber.
Note 5. This design also allows combining with mutation detection.
Prophetic Example 8—Use of PCR-LDR-Taqman™ or PCR-LDR Unitaq Detection for Low Abundance Mutation and/or CpG Methylation Identification and Quantification Directly from PlasmaThe assay described below would use a cartridge with 48×48=2,304 subdivisions for 221, 1846 micro-well array format, with 96 micro-wells per subdivision, and 4,608 micro-wells per column (acoustic droplet ejection into microtiter array plate): Please see
The assay may be designed to detect and quantify 48, 96, or 192 potential targets. Preparation of the microtiter plate would require spotting UniTaq or Universal Tag primer and target-specific probe sets, and drying them down before use of microtiter plate.
1. Distribute initial sample into 48 wells or Primary PCR Reaction Chambers. Highest level of DNA in plasma=10,000 genome equivalents. On average, 200 copies of each target per Primary PCR Reaction Chamber, with at most 1 mutation. Perform 10-40 cycles of locus-specific PCR with blocking PNA or LNA to reduce amplification of wild-type DNA. Optional: Use dUTP during PCR reaction (and pre-treat with UDG to avoid carryover contamination of initial sample).
2. Dilute products of each well or Primary PCR Reaction Chamber with LDR primers and buffers and distribute into Secondary LDR Reaction Chambers. Perform 20 cycles of LDR using allele-specific primers with UniTaq tails, in groups of 16, 32, or 64 primer sets. LDR primers for different mutations of the same gene may be designed to give the same signal in the same subdivision. LDR reactions may be performed in the same reaction chamber, or in 2 separate reaction chambers, and then re-combined.
3. Add UniTaq master mix and UDG and distribute products of each well or Secondary LDR Reaction Chamber into 48 subdivisions, respectively, containing 96 micro-pores. The subdivisions have been pre-spotted with appropriate UniTaq primers, and/or probes; (see
For Identification and Quantification of Low Abundance CpG Methylation in Plasma (when Combined with Mutation; Using Bisulfite-PCR-LDR-Taqman™, or Bisulfite-PCR-LDR-Unitaq Detection. See
1. Digest sample with Bsh1236I in Initial Reaction Chamber. Treat with Bisulfite. Re-purify DNA strands.
2. Distribute bisulfite treated sample into 48 wells or Primary PCR Reaction Chambers. Highest level of DNA in plasma after RE cleavage=200 genome equivalents. Perform 10-40 cycles of locus-specific PCR with optional blocking PNA or LNA to reduce amplification of wild-type DNA, if needed. Optional: Use dUTP during PCR reaction.
3. Dilute products of each well or Primary PCR Reaction Chamber with LDR primers and buffers and distribute into Secondary LDR Reaction Chambers. Perform 20 cycles of LDR using methyl-specific primers with UniTaq tails, in groups of 16, 32, or 64 primer sets. LDR primers for different methylation regions, i.e. top and bottom strand of the same promoter region may be designed to give the same signal in the same subdivision. LDR reactions may be performed in the same reaction chamber, or in 2 separate reaction chambers, and then re-combined.
4. Add UniTaq master mix and UDG and distribute products of each well or Secondary LDR Reaction Chamber into 48 subdivisions, respectively, containing 96 micro-pores. The subdivisions have been pre-spotted with appropriate UniTaq primers, and/or probes; (see
See also, notes 1-5 for Example 7 above.
Prophetic Example 9—Use of PCR-PCR-Taqman™ or PCR-PCR Unitaq Detection for Exact Enumeration of Both Rare and Overexpressed lncRNA, mRNA, or Splice VariantsThe assay described below would use a cartridge with 24×16=384 (or optional 768) subdivisions for 9,216 micro-well or micro-pore array format, with 24 micro-wells or micro-pores per subdivision, and 384 micro-wells or micro-pores per column (using pre-spotted array): Please see
The assay may be designed to detect and quantify 384 potential targets. Preparation of the cartridge would require spotting 16, 32, or 64 nested PCR primer pairs on the front side of the array, with adding UniTaq or Universal Tag and target-specific probe and primer sets at right angles and drying them down before cartridge assembly.
1. Initial multiplexed reverse-transcription/amplification of the sample—384 potential targets. Perform 7 cycles of multiplexed RT-PCR in the Initial Reaction Chamber, maximum of 128 copies of each original transcript. All reverse transcription and PCR primers should include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
2. Distribute initial multiplexed products into 6 Primary PCR Reaction Chambers. Average distribution in each Primary PCR Reaction Chamber is 20 copies of each original transcript. Perform 10 cycles of nested PCR using primers with UniTaq tails, in groups of 16, 32, or 64 primer unique sets for each Primary PCR Reaction Chamber, for a maximum of 20,480 copies of each original transcript. For this example, three different sets of transcripts would be accurately quantified, where the minimum number would be on the order of 1 original RNA transcript, yielding 20,480 copies, 100 original RNA transcripts, yielding 2,048,000 copies, and 10,000 original RNA transcripts, yielding 204,800,000 copies.
3. The six Primary PCR Reaction Chambers are designed to retain a certain percentage of the volume of the liquid in the reaction after draining. For this example, the full volume of the nested PCR reaction will be designated as 80 units, and the amount retained as 40 units or less. For this illustration, the multiplexed amplification primer sets for Primary PCR Reaction Chambers 1 & 2 are for low-level transcripts (retaining 40 units of liquid), for Primary PCR Reaction Chambers 3 & 4 are for medium-level transcripts (retaining 10 units of liquid), and for Primary PCR Reaction Chambers 5 & 6 are for high-level transcripts (retaining 3 units of liquid). After the first draining, below are the calculations for liquid and minimum copies remaining:
A fresh 40μ of master-mix with antibody to inhibit polymerase is added to the remaining liquid, and drained again:
A fresh 40μ of master-mix with antibody to inhibit polymerase is added to the remaining liquid, and drained again:
A fresh 40μ of master-mix is added to the remaining liquid, and now pushed upward, divided equally 4 Secondary Reaction/Dilution Chambers, A, B, C, and D, which have a total volume of 20 units, and can retain 10 units or less.
SR-Chambers 3 & 4, as well as 5 & 6 will have about twice the number of molecules as above
A fresh 10μ of master-mix is added to the remaining liquid in the upper chambers, and drained again:
SR-Chambers 3 & 4, as well as 5 & 6 will have about twice the number of molecules as above
A fresh 10μ of master-mix is added to the remaining liquid in the upper chambers, and drained again:
SR-Chambers 3 & 4, as well as 5 & 6 will have about twice the number of molecules as above
At the end, sufficient mastermix is added as all the remaining products and reagents are moved to a larger mixing chamber, in preparation for moving into the micro-pores.
4. Distribute products of each Secondary Reaction/Dilution Chamber into 384 micro-wells or micro-pores. On average, each A Secondary Reaction/Dilution Chamber will get 5 copies of each original transcript, with progressively less in the B, C, and D Secondary Reaction/Dilution Chambers. PCR amplify 1, 2, or 4 potential products in each well using the UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers. Poisson distribution in 24 micro-pores will provide enumeration for very low copy transcripts in the A Secondary Reaction/Dilution Chamber, while Poisson distribution across 24 micro-pores in the B, C, and D Secondary Reaction/Dilution Chambers will provide enumeration for high copy transcripts across three to four orders of magnitude.
Secondary Reaction/Dilution Chambers 1 & 2 will accurately enumerate starting transcripts ranging from 1 (filling on average about 5 of the 24 micro-pores of the “A” column) to about 1,500-3,000 (filling on average about 15-21 of the 24 micro-wells or micro-pores of the “D” column).
Secondary Reaction/Dilution Chambers 3 & 4 will accurately enumerate starting transcripts ranging from 100 (filling on average about 10 of the 24 micro-pores of the “A” column) to about 150,000-300,000 (filling on average about 15-21 of the 24 micro-wells or micro-pores of the “D” column).
Secondary Reaction/Dilution Chambers 5 & 6 will accurately enumerate starting transcripts ranging from 10,000 (filling on average about 10 of the 24 micro-pores of the “A” column) to about 15,000,000-30,000,000 (filling on average about 15-21 of the 24 micro-wells or micro-pores of the “D” column).
Note 1: The success of this assay format depends on there being no primer dimers formed by the UniTaq primers, e.g. with the nested primers. Using 3′-blocked UniTaq primers and RNaseH2 to unblock at an RNA base would solve this problem. The same 3′ block/RNase trick may also be used on the nested primer set; however, there is a slight risk such primers would be less effective since sequence drift of the pathogen may prevent the primers from amplifying that particular target.
Note 2: One advantage of using the UniTaq primers is they may be placed very close to each other such that multiple nested products may be generated off a single initial target transcript. This allows primer design with 2 nested primer sets within each transcript region. This would allow double verification for a given transcript. Another advantage of this approach is it would limit the number of PCR primers in the initial multiplexed reaction. A further advantage is that primers can be designed such that those signals are displayed in different subdivisions to mitigate any target-independent (false) signals.
Note 3: As an alternative to designing different sets of chambers with different dilutions, separate heating elements may run different chambers under different conditions, including changing the number of PCR cycles.
Prophetic Example 10—Use of PCR-PCR-Taqman™ or PCR-PCR Unitaq Detection for Exact Enumeration of Both Rare and Overexpressed lncRNA, mRNA, or Splice VariantsThe assay described below would use a cartridge with 48×48=2,304 subdivisions for 221,1846 micro-well array format, with 96 micro-wells per subdivision, and 4,608 micro-wells per column (acoustic droplet ejection into microtiter array plate): Please see
The assay may be designed to detect and quantify 576, or 1,152 potential targets. Preparation of the microtiter plate would require spotting UniTaq or Universal Tag primer and target-specific probe sets, and drying them down before use of microtiter plate.
1. Initial multiplexed reverse-transcription/amplification of the sample—576, or 1,152 potential targets. Perform 10 cycles of multiplexed PCR, maximum of 1,024 copies of each original RNA molecule in the Initial Reaction Chamber. If needed, use “tandem” PCR primers. Also, all PCR primers may include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
2. Distribute initial multiplexed products into 48 wells or Primary PCR Reaction Chambers. Average distribution in each well is 20 copies of each original RNA target. Perform 3-4 cycles of nested PCR using primers with UniTaq tails, in groups of 24, or 48 primer sets, for a maximum of 160-320 copies of each original RNA molecule.
3. Distribute products of each well or Primary PCR Reaction Chamber into 2 or 4 sets of 24 or 12 subdivisions respectively containing 96 micro-pores. When using 2 sets, the second set is a 100/1 dilution of the first. When using 4 sets, each set is a 20/1 dilution of the previous set. This allows coverage of RNA molecules present across many orders of magnitude. On average, each initial subdivision will get 12 copies of each original RNA molecule, with a given micro-pore getting one or zero copies of original RNA. If RNA is present in higher numbers, each subdivision will get additional copies. PCR amplify 1, 2, or 4 potential products in each micro-pore using the pre-spotted UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. Use one, two, or four different fluorescent dyes on the UniTaq primers. Poisson distribution in 96 micro-pores across 2 or 4 dilution sets will provide some degree of enumeration for very low copy RNA, as well as higher copy RNA in sample.
See also, notes 1-2 for Example 9 above.
Prophetic Example 11—Use of PCR-PCR-Sequencing for Unknown Pathogen Identification and GenotypingThe assay described below would use a cartridge with 48×32=1,536 subdivisions for 4,239,360 micro-pore array format for targeted sequencing, with 2,760 micro-pores per subdivision, and 88,320 micro-pores per column. For multiplexed amplification with immobilized primer, see
The assay may be designed to identify and genotype 1,536 potential targets. Preparation of the cartridge would require spotting 48×32 PCR primer pairs on the front side of the array, with 32×48 PCR sequencing primers on the back side and drying them down before cartridge assembly.
1. Initial multiplexed amplification of the sample—1,536 potential targets. Perform 10 cycles of PCR in the Initial Reaction Chamber, maximum of 1,024 copies of each original pathogen.
2. Distribute initial multiplexed products into 48 Primary PCR Reaction Chambers. Average distribution in each Primary PCR Reaction Chamber is 20 copies of each original pathogen target. Nested, locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 5 cycles of nested PCR in groups of 32, maximum of 640 copies of each original pathogen. Optional, remove universal primer sequence from product with UDG/APE1 to improve hybridization of product to immobilized primer in micro-pores.
3. Distribute products of each Primary PCR Reaction Chamber into 88,320 micro-pores. On average, each subdivision (comprising 2,760 micro-pores) will get 20 copies of each original pathogen. PCR amplify multiple products in each micro-pore, and then melt off non-anchored strand.
4. Add 48 sequencing primers for each of the 48 targets in 32 subdivisions at right angles. Allows for sequencing of 1,536 potential targets simultaneously. Poisson distribution in 2,760 micro-pores enables enumeration of low-abundance targets.
PCR-PCR-Sequencing for Unknown Pathogen Identification and Genotyping with Adding Sequencing Primers at the Same 48 Subdivisions (See
If sequencing primers are added in the same orientation, i.e. without subdivision, there are 48×n potential targets, with 88,320/n micro-pores/subdivision.
There are several ways to approach this. One approach is that in general, bacterial pathogens are present at lower levels than viral pathogens. The original PCR cycles could include an RT-step for Viral pathogens, without the second primer, such that they aren't amplified as much as the bacterial fragments are. Also, the original PCR step could be for fewer cycles, and the nested PCR step could also be for fewer cycles still. Then, even if some pathogens are present at higher numbers, with 88,320 micro-pores/section (i.e. column), even if some are present at 2,000 copies, and others at 5 copies, sequencing 32 targets per subdivision would not be unreasonable. Note, the sets of 32 sequencing primers×48 would also be printed on the device. This would allow for detecting 1,536 potential targets simultaneously in a single sequencing run, as well as take advantage of the Poisson distribution in 2,760 micro-pores.
Another approach is to incorporate 8-12 bases of unique sequence in-between the universal primer and the target-specific sequence of the nested PCR primer on the side that does not get attached to the solid support. This would allow for sequencing sets of potential targets by using the 8-12 bases on the 3′ side of more universal sequencing primers.
Another approach is to use different universal primers for each set of nested PCR primers, and then print the desired universal sets within the micro-pores, in 32 sections. This would effectively make sure that each amplification product goes to a defined row and column. The advantage of this approach is that it also allows for separate Taqman™ or LDR detection of various products.
In a variation of this idea, the universal primer sequences are the UniTaq sequences. The desired UniTaq primers are printed within the pores, in 32 sets. This approach does not require immobilization of all the primers, although they can be transiently kept in place using hybridization to dendrimers.
Note that with 4-color LDR-FRET detection, splitting into 48 sections, this still allows for highly accurate enumeration of 192 targets simultaneously. Since each of the 48 sections has a different set of (e.g. 16) targets amplified, one could add all 384 LDR primers simultaneously, and they would sort themselves out. This would allow accurate quantification and enumeration of 768 targets in just 4 LDR reactions.
Prophetic Example 12—Use of PCR-PCR-Sequencing for Unknown Pathogen Identification and GenotypingThe assay described below would use a cartridge with 48 double-columns×48 double-rows=2,304 subdivisions for 25,436,160 micro-pore array format for targeted sequencing, with 11,040 micro-pores per subdivision, and 529,920 micro-pores per column. For multiplexed amplification with immobilized primer, see
The assay may be designed to identify and genotype 2,304 to 9,216 potential targets. Preparation of the cartridge would require spotting 48×48 PCR primer pairs on the front side of the array, with 48×48 PCR sequencing primers on the back side and drying them down before cartridge assembly.
1. Initial multiplexed amplification of the sample—2,304 to 9,216 potential targets. Perform 10 cycles of PCR in the Initial Reaction Chamber, maximum of 1,024 copies of each original pathogen.
2. Distribute initial multiplexed products into 48 wells or Primary PCR Reaction Chambers. Average distribution in each well or Primary PCR Reaction Chamber is 20 copies of each original pathogen target. Nested, locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 2-3 cycles of nested PCR in groups of 32, maximum of 80 to 160 copies of each original pathogen. Optional, remove universal primer sequence from product with UDG/APE1 to improve hybridization of product to immobilized primer in micro-pores.
3. Distribute products of each well or Primary PCR Reaction Chamber into 529,920 micro-pores. PCR amplify multiple products in each micro-pore and melt off non-anchored strand.
PCR-PCR-Sequencing for Unknown Pathogen Identification and Genotyping with Adding Sequencing Primers at the Same 48 Subdivisions:
If sequencing primers are added in the same orientation, i.e. without subdivision, there are 48×n potential targets, with 529,920/n micro-pores/subdivision.
There are several ways to approach this. One approach is that in general, bacterial pathogens are present at lower levels than viral pathogens. The original PCR cycles could include an RT-step for Viral pathogens, without the second primer, such that they aren't amplified as much as the bacterial fragments are. Also, the original PCR step could be for fewer cycles. Then, even if some pathogens are present at higher numbers, with 529,920 micro-pores/section (column), even if some are present at 2,000 copies, and others at 5 copies, sequencing 32 targets per section (column) would not be unreasonable. Note, the sets of 192 sequencing primers×48 would also be distributed into the device. This would allow for detecting 9,216 potential targets simultaneously in a single sequencing run, as well as take advantage of the Poisson distribution in 529,920 micro-pores.
Another approach is to incorporate 8-16 bases of unique sequence in-between the universal primer and the target-specific sequence of the nested PCR primer on the side that does not get attached to the solid support. This would allow for sequencing sets of potential targets by using the 8-16 bases on the 3′ side of more universal sequencing primers.
A first set of 8-16 sequencing primers may comprise a common 5′ sequence (16 bases), and variable 3′ sequences (8 bases). Or, a second set of 64-256 sequencing primers may comprise a common 5′ sequence (8 bases), a variable middle sequence (8 bases, 8-16 variants) and hyper-variable 3′ sequences (8 bases, 64-256 variants).
Prophetic Example 13—Use of PCR-PCR-Sequencing for Low Abundance Mutation and/or CpG Methylation Identification and Enumeration Directly from PlasmaThe assay described below would use a cartridge with 48×32=1,536 subdivisions for 4,239,360 micro-pore array format for targeted sequencing, with 2,760 micro-pores per subdivision, and 88,320 micro-pores per column. See
1. Distribute initial sample into 48 Primary PCR Reaction Chambers. Highest level of DNA in plasma=10,000 genome equivalents. On average, 200 copies of each target per Primary PCR Reaction Chamber, with at most 1 mutation. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 3 cycles of fragment identifier PCR for both strands, each strand covering slightly different sequences. Yields 4 copies of top strand, and 4 copies of bottom strand.
2. Treat with UDG/APE1, and distribute products of each Primary PCR Reaction Chamber into 88,320 micro-pores. Assuming 75% capture, a given target will have about 1200 copies per section (column), and if a mutation is present, there should be about 3 copies of the “Watson strand” and about 3 copies of the “Crick strand”. PCR amplify multiple products in each well using nested target-specific primers and universal primers and melt off non-anchored strand.
3. Add 72 sequencing primers—covers 36 target regions, for both Watson and Crick strand, including overlapping regions when needed. Generate about 80 bases of sequence information, plus 10 bases of unique fragment identifier barcode.
4. Add an additional 72 sequencing primers. The current cartridge easily has room for 4 rounds of sequencing=288 primers—covers 144 target regions, both strands, with accurate enumeration of each mutation.
Note 1: The original nested primers may also be used as sequencing primers.
Note 2: The nested primers may be designed to contain different sets of universal sequences comprising the master universal sequence and then 8-12 bases on the 3′ end to uniquely sequence different fragments, such that on average, 72 products are sequenced per individual sequencing primer. Repeat with next sequencing primer to sequence next 72 fragments.
For Identification and Quantification of Low Abundance CpG Methylation in Plasma (when Combined with Mutation; Using Bisulfite-PCR-PCR Sequencing. See
1. Digest sample with Bsh1236I in the Initial Reaction Chamber. Treat with Bisulfite. Re-purify strands.
2. Distribute bisulfate treated sample into 48 Primary PCR Reaction Chambers. Highest level of DNA in plasma after RE cleavage=200 genome equivalents. On average, 4 copies of each target per Primary PCR Reaction Chamber, with at most 1 being methylated. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 3 cycles of fragment identifier PCR for both strands, each strand covering slightly different sequences. Yields 4 copies of top strand, and 4 copies of bottom strand of originally methylated DNA.
3. Treat with UDG/APE1, and distribute products of each Primary PCR Reaction Chamber into 88,320 micro-pores. Assuming 75% capture, a given target will have about 16 copies per Primary PCR Reaction Chamber, and if a methylated region is present, there should be about 3 copies of the “Watson strand” and about 3 copies of the “Crick strand”. PCR amplify multiple products in each well using nested target-specific primers and universal primers and melt off non-anchored strand.
4. Add as many sequencing primers as desired to cover methylated regions. (Theoretically, could cover 2,760 methylated regions in one sequencing run, with accurate enumeration of every methylated region.)
Note 1. The original nested primers may also be used as sequencing primers.
For Identification and Quantification of Low Abundance CpG Methylation in Plasma Using Bisulfite-PCR-PCR Sequencing (when Done Alone):
1. Digest sample with Bsh1236I in the Initial Reaction Chamber. Treat with Bisulfite. Re-purify strands.
2. Distribute bisulfate treated sample into 48 Primary PCR Reaction Chambers. Highest level of DNA in plasma after RE cleavage=200 genome equivalents. On average, 4 copies of each target per Primary PCR Reaction Chamber, with at most 1 being methylated. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 11 cycles of fragment identifier PCR for one strand. Yields 1,024 copies of one strand of originally methylated DNA.
3. Treat with UDG/APE1, and distribute products of each Primary PCR Reaction Chamber into 88,320 micro-pores. Assuming 75% capture, a given target will have about 100 copies per section (column), and if a methylated region is present, there should be about 24 copies of that strand. PCR amplify multiple products in each well and melt off non-anchored strand.
4. Add 12 sequencing primers for each 12 targets in 32 subdivisions at right angles. Allows for sequencing of 384 potential methylated targets simultaneously. Poisson distribution in 2,760 micro-pores enables enumeration of methylated targets. Total of 384 potential methylated target regions can be evaluated simultaneously, with accurate enumeration of every methylated region.
Note 1. The original target-specific second primers may also be used as sequencing primers.
Prophetic Example 14—Use of PCR-PCR-Sequencing for Low Abundance Mutation and/or CpG Methylation Identification and Enumeration Directly from PlasmaThe assay described below would use a cartridge with 48 double-columns×48 double-rows=2,304 subdivisions for 25,436,160 micro-pore array format for targeted sequencing, with 11,040 micro-pores per subdivision, and 529,920 micro-pores per column. See
1. Distribute initial sample into 48 wells or Primary PCR Reaction Chambers. Highest level of DNA in plasma=10,000 genome equivalents. On average, 200 copies of each target per Primary PCR Reaction Chamber, with at most 1 mutation. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 3 cycles of fragment identifier PCR for both strands, each strand covering slightly different sequences. Yields 4 copies of top strand, and 4 copies of bottom strand.
2. Treat with UDG/APE1 and distribute products from each Primary PCR Reaction Chambers into 529,920 micro-pores. Assuming 75% capture, a given target will have about 1200 copies per section (column), and if a mutation is present, there should be about 3 copies of the “Watson strand” and about 3 copies of the “Crick strand”. PCR amplify multiple products in each well using nested target-specific primers and universal primers and melt off non-anchored strand.
3. Add 256 sequencing primers—covers 128 target regions, for both Watson and Crick strand, including overlapping regions when needed. Generate about 80 bases of sequence information, plus 10 bases of unique fragment identifier barcode. Approximately 307,200 micro-pores out of the 529,920 micro-pores will generate sequence information, with about 75% of these providing reads from a single PCR product per sequencing round.
4. Add an additional 256 sequencing primers as often as needed to sequence as many targeted regions as needed.
Note 1: The original nested primers may also be used as sequencing primers.
Note 2: The nested primers may be designed to contain different sets of universal sequences comprising the master universal sequence and then 8-16 bases on the 3′ end to uniquely sequence different fragments, such that on average, 256 products are sequenced per individual sequencing primer. Repeat with next sequencing primer to sequence next 256 fragments.
For Identification and Quantification of Low Abundance CpG Methylation in Plasma (when Combined with Mutation; Using Bisulfite-PCR-PCR Sequencing. See
1. Digest sample with Bsh1236I in the Initial Reaction Chamber. Treat with Bisulfite. Re-purify strands.
2. Distribute bisulfite treated sample into 48 wells or Primary PCR Reaction Chambers. Highest level of DNA in plasma after RE cleavage=200 genome equivalents. On average, 4 copies of each target per Primary PCR Reaction Chamber, with at most 1 being methylated. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 3 cycles of fragment identifier PCR for both strands, each strand covering slightly different sequences. Yields 4 copies of top strand, and 4 copies of bottom strand of originally methylated DNA.
3. Treat with UDG/APE1 and distribute products from each Primary PCR Reaction Chamber into 529,920 micro-pores. Assuming 75% capture, a given target will have about 16 copies per section (column), and if a methylated region is present, there should be about 3 copies of the “Watson strand” and about 3 copies of the “Crick strand”. PCR amplify multiple products in each well using nested target-specific primers and universal primers and melt off non-anchored strand.
4. Add as many sequencing primers as desired to cover methylated regions. Theoretically, could cover 19,200 methylated regions in one sequencing run, with accurate enumeration of every methylated region. Thus, if a master universal sequence is used just for the methylated regions, this single primer could cover all the methylated regions in a single run.
Note 1. The original nested primers may also be used as sequencing primers.
For Identification and Quantification of Low Abundance CpG Methylation in Plasma Using Bisulfite-PCR-PCR Sequencing (when Done Alone):
1. Digest sample with Bsh1236I in Initial Reaction Chamber. Treat with Bisulfite. Re-purify strands.
2. Distribute bisulfite treated sample into 48 wells or Primary PCR Reaction Chambers. Highest level of DNA in plasma after RE cleavage=200 genome equivalents. On average, 4 copies of each target per Primary PCR Reaction Chamber, with at most 1 being methylated. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 11 cycles of fragment identifier PCR for one strand. Yields 1,024 copies of one strand of originally methylated DNA.
3. Treat with UDG/APE1 and distribute products from each Primary PCR Reaction Chamber into 529,920 micro-pores. Assuming 75% capture, a given target will have about 100 copies per section (column), and if a methylated region is present, there should be about 24 copies of that strand. PCR amplify multiple products in each well and melt off non-anchored strand.
4. Add as many sequencing primers as desired to cover methylated regions. Theoretically, could cover 19,200 methylated regions in one sequencing run, with accurate enumeration of every methylated region. Thus, if a master universal sequence is used just for the methylated regions, this single primer could cover all the methylated regions in a single run.
Note 1. The original target-specific second primers may also be used as sequencing primers.
Prophetic Example 15—Use of PCR-PCR-Sequencing for Non-Invasive Pre-Natal Testing (NIPT of Trisomy Directly from PlasmaThe assay described below would use a cartridge with 48×32=1,536 subdivisions for 4,239,360 micro-pore array format for targeted sequencing, with 2,760 micro-pores per subdivision, and 88,320 micro-pores per column. See
1. Adjust DNA in plasma/sample to 2,000 genome equivalents. Distribute initial sample into 48 Primary PCR Reaction Chambers. On average, 40 copies of each locus per Primary PCR Reaction Chamber, with different SNPs. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 3 cycles of fragment identifier PCR for both strands, each strand covering slightly different sequences. Yields 4 copies of top strand, and 4 copies of bottom strand.
2. Treat with UDG/APE1 and distribute products of each Primary PCR Reaction Chamber into 88,320 micro-pores. Assuming 75% capture, a given locus will have about 240 copies per section i.e. column (120 for Watson strand and 120 for Crick strand). PCR amplify multiple products in each well using nested locus-specific primers and universal primers and melt off non-anchored strand.
3. Add 368 sequencing primers (or one primer, see note 2 below)—covers 184 locus regions, for both Watson and Crick strand. Generate about 50 bases of sequence information, plus 10 bases of unique fragment identifier barcode.
4. Add an additional 368 (or one primer, see note 2 below) sequencing primers. The current cartridge has room for 4 rounds of sequencing=covers 736 locus regions, both strands, with accurate enumeration of each SNP on both the Watson and Crick strand.
Basic idea is to enumerate how many copies of each strand are present. Since the Watson strands should match the Crick strands in each of the 48 sections, i.e. columns (since they are generated from a given fragment with one of each strand), this is an internal control for loss of strands or other errors. Multiple unique loci on Chromosomes 2 (control), 13, 18, 21, X, and Y are used to establish copy number as well as identify trisomy or other chromosomal copy changes.
The above calculations are based on filling on average about 50% of the micro-pores. (Poisson distribution: mean lambda=0.4; Initial percentage x=0). Under such conditions, approximately 60% of the micro-pores will not give any sequencing reads, about 30% are unique (i.e. single reads), about 7.5% will give double reads, and about 1.3% will give triple reads. On a practical level, the single reads are unambiguous for distinguishing SNPs. The double reads may be used to determine loci, but double reads should not be used to distinguish SNPs. Between the single and double reads, over 90% of the strands are covered, and since that distribution is essentially random, this approach should provide highly accurate enumeration of each strand present in the initial sample.
Note 1: The original nested primers may also be used as sequencing primers.
Note 2: The nested primers may be designed to contain different sets of universal sequences comprising the master universal sequence and then 8-12 bases on the 3′ end to uniquely sequence different fragments, such that on average, 368 products are sequenced per individual sequencing primer. Repeat with next sequencing primer to sequence next 368 fragments.
Prophetic Example 16—Use of PCR-PCR-Sequencing for Non-invasive Pre-natal Testing (NIPT of Trisomy Directly from PlasmaThe assay described below would use a cartridge with 48 double-columns×48 double-rows=2,304 subdivisions for 25,436,160 micro-pore array format for targeted sequencing, with 11,040 micro-pores per subdivision, and 529,920 micro-pores per column. See
1. Adjust DNA in plasma/sample to 2,000 genome equivalents. Distribute initial sample into 48 Primary PCR Reaction Chambers. On average, 40 copies of each locus per Primary PCR Reaction Chamber, with different SNPs. Locus-specific primers are unblocked with RNaseH2 only when bound to target. Perform 3 cycles of fragment identifier PCR for both strands, each strand covering slightly different sequences. Yields 4 copies of top strand, and 4 copies of bottom strand.
2. Treat with UDG/APE1 and distribute products of each Primary PCR Reaction Chamber into 529,920 micro-pores. Assuming 75% capture, a given locus will have about 240 copies per section, i.e. column (120 for Watson strand and 120 for Crick strand). PCR amplify multiple products in each well using nested locus-specific primers and universal primers and melt off non-anchored strand.
3. Add 2,208 sequencing primers (or one primer, see note 2 below)—covers 1,104 locus regions, for both Watson and Crick strand. Generate about 50 bases of sequence information, plus 10 bases of unique fragment identifier barcode.
4. Add an additional 2,208 (or one primer, see note 2 below) sequencing primers.
Basic idea is to enumerate how many copies of each strand are present. Since the Watson strands should match the Crick strands in each of the 48 sections, i.e. columns (since they are generated from a given fragment with one of each strand), this is an internal control for loss of strands or other errors. Multiple unique loci on Chromosomes 2 (control), 13, 18, 21, X, and Y are used to establish copy number as well as identify trisomy or other chromosomal copy changes.
The above calculations are based on filling on average about 50% of the micro-pores. (Poisson distribution: mean lambda=0.4; Initial percentage x=0). Under such conditions, approximately 60% of the micro-pores will not give any sequencing reads, about 30% are unique (i.e. single reads), about 7.5% will give double reads, and about 1.3% will give triple reads. On a practical level, the single reads are unambiguous for distinguishing SNPs. The double reads may be used to determine loci but should not be used to distinguish SNPs. Between the single and double reads, over 90% of the strands are covered, and since that distribution is essentially random, this approach should provide highly accurate enumeration of each strand present in the initial sample.
Note 1: The original nested primers may also be used as sequencing primers.
Note 2: The nested primers may be designed to contain different sets of universal sequences comprising the master universal sequence and then 8-16 bases on the 3′ end to uniquely sequence different fragments, such that on average, 368 products are sequenced per individual sequencing primer. Repeat with next sequencing primer to sequence next 1,104 fragments.
Prophetic Example 17—Use of PCR-PCR-Taqman™ or PCR-PCR Unitaq Detection for Exact Enumeration of Both Rare and Overexpressed lncRNA, mRNA, or Splice VariantsThe assay described below would use a cartridge with 48×32=1,536 subdivisions for 4,239,360 micro-pore array format for targeted sequencing, with 2,760 micro-pores per subdivision, and 88,320 micro-pores per column. Please see
1. Initial multiplexed reverse-transcription/amplification of the sample—1,536 potential targets. Perform 9 cycles of PCR in the Initial Reaction Chamber, maximum of 512 copies of each original transcript. All reverse transcription and PCR primers should include identical 5′ tail sequences, preferably 10-11 bases to suppress amplification of primer dimers.
2. Distribute initial multiplexed products into 24 Primary PCR Reaction Chambers. Average distribution in each Primary PCR Reaction Chamber is 20 copies of each original transcript. Perform 10 cycles of nested PCR using primers with UniTaq tails, in groups of 32 primer unique sets for each Primary PCR Reaction Chamber, for a maximum of 20,480 copies of each original transcript. For this example, three different sets of transcripts would be accurately quantified, where the minimum number would be on the order of 1 original RNA transcript, yielding 20,480 copies, 100 original RNA transcripts, yielding 2,048,000 copies, and 10,000 original RNA transcripts, yielding 204,800,000 copies.
3. The 24 Primary PCR Reaction Chambers are designed to retain a certain percentage of the volume of the liquid in the reaction after draining. For this example, the full volume of the nested PCR reaction will be designated as 80 units, and the amount retained as 40 units or less. For this illustration, the multiplexed amplification primer sets for Primary PCR Reaction Chambers 1-8 are for low-level transcripts (retaining 40 units of liquid), for Primary PCR Reaction Chambers 9-16 are for medium-level transcripts (retaining 10 units of liquid), and for Primary PCR Reaction Chambers 17-24 are for high-level transcripts (retaining 3 units of liquid). After the first draining, below are the calculations for liquid and minimum copies remaining:
A fresh 40μ of master-mix with antibody to inhibit polymerase is added to the remaining liquid, and drained again:
A fresh 40μ of master-mix with antibody to inhibit polymerase is added to the remaining liquid, and drained again:
A fresh 40μ of master-mix is added to the remaining liquid, and now pushed upward, divided equally into Secondary Reaction/Dilution Chambers, A and B, which have a total volume of 20 units, and can retain 10 units or less.
SR-Chambers 9-16, as well as 17-24 will have about twice the number of molecules as above
A fresh 10μ of master-mix is added to the remaining liquid in the upper chambers, and drained again:
SR-Chambers 9-16, as well as 17-24 will have about twice the number of molecules as above
At the end, sufficient mastermix is added as all the remaining products and reagents are moved to a larger mixing chamber, in preparation for moving into the micro-pores.
4. Distribute products of each Secondary Reaction/Dilution Chamber into 88,320 micro-pores. On average, each A Secondary Reaction/Dilution Chamber will get 5 copies of each original transcript, with about 200-fold less in the B Secondary Reaction/Dilution Chamber. PCR amplify potential products in each micro-pore using the UniTaq primer sets and determine Ct value in each micro-pore of each subdivision. (Optional: the total number of transcripts may be doubled or quadrupled by using two, or four different fluorescent dyes on the UniTaq primers). Poisson distribution in 2,760 micro-pores will provide enumeration for very low copy transcripts in the A Secondary Reaction/Dilution Chambers, while Poisson distribution across 2,760 micro-pores in the B Secondary Reaction/Dilution Chambers will provide enumeration for high copy transcripts across three orders of magnitude.
Secondary Reaction/Dilution Chambers 1-8 will accurately enumerate starting transcripts ranging from 1 (filling on average about 5 of the 2,760 micro-pores of the “A” column) to about 110,000-220,000 (filling on average about 1,766-2,290 of the 2,760 micro-pores of the “B” column).
Secondary Reaction/Dilution Chambers 3 & 4 will accurately enumerate starting transcripts ranging from 100 (filling on average about 10 of the 2,760 micro-pores of the “A” column) to about 11,000,000-22,000,000 (filling on average about 1,766-2,290 of the 2,760 micro-pores of the “B” column).
Secondary Reaction/Dilution Chambers 5 & 6 will accurately enumerate starting transcripts ranging from 10,000 (filling on average about 10 of the 2,760 micro-pores of the “A” column) to about to about 1,100,000,000-2,200,000,000 (filling on average about 1,766-2,290 of the 2,760 micro-pores of the “B” column).
Note 1: The success of this assay format depends on there being no primer dimers formed by the UniTaq primers, e.g. with the nested primers. Using 3′-blocked UniTaq primers and RNaseH2 to unblock at an RNA base would solve this problem. The same 3′ block/RNase trick may also be used on the nested primer set, however there is a slight risk such primers would be less effective since sequence drift of the pathogen may prevent the primers from amplifying that particular target.
Note 2: One advantage of using the UniTaq primers is they may be placed very close to each other such that multiple nested products may be generated off a single initial target transcript. This allows primer design with 2 nested primer sets within each transcript region. This would allow double verification for a given transcript. Another advantage of this approach is it would limit the number of PCR primers in the initial multiplexed reaction. A further advantage is that primers can be designed such that those signals are displayed in different sections (columns) to mitigate any target-independent (false) signals.
Note 3: As an alternative to designing different sets of chambers with different dilutions, separate heating elements may run different chambers under different conditions, including varying the number of PCR cycles.
With Adding Sequencing Primers at the Same 48 Sections (i.e. Columns) for Exact Enumeration of Both Rare and Overexpressed lncRNA, mRNA, or Splice Variants:
If sequencing primers are added in the same orientation, i.e. without subdivision, there are 48×n potential targets, with 88,320/n micro-pores/subdivision.
There are two ways to approach this. One approach is that in general, bacterial pathogens are present at lower levels than viral pathogens. The original PCR cycles could include an RT-step for viral pathogens, without the second primer, such that they aren't amplified as much as the bacterial fragments are. Also, the original PCR step could be for fewer cycles, and the nested PCR step could also be for fewer cycles still. Then, even if some pathogens are present at higher numbers, with 88,320 micro-pores/section (column), even if some are present at 2,000 copies, and others at 5 copies, sequencing 32 targets per section would not be unreasonable. Note, the sets of 32 sequencing primers×48 would also be printed on the device. This would allow for detecting 1,536 potential targets simultaneously in a single sequencing run, as well as take advantage of the Poisson distribution in 2,760 micro-pores.
Another approach is to incorporate 8-12 bases of unique sequence in-between the universal primer and the target-specific sequence of the nested PCR primer on the side that does not get attached to the solid support. This would allow for sequencing sets of potential targets by using the 8-12 bases on the 3′ side of more universal sequencing primers.
Another approach is to use different universal primers for each set of nested PCR primers, and then print the desired universal sets within the pores, in 32 sections. This would effectively make sure that each amplification product goes to a defined row and column. The advantage of this approach is that it also allows for separate Taqman™ or LDR detection of various products.
In a variation of this idea, the universal primer sequences are the UniTaq sequences. The desired UniTaq primers are printed within the pores, in 32 sets. This approach does not require immobilization of all the primers, although they can be transiently kept in place using hybridization to dendrimers.
Note that with 4-color LDR-FRET detection, splitting into 48 sections, this still allows for highly accurate enumeration of 192 targets simultaneously. Since each of the 48 sections has a different set of (e.g. 16) targets amplified, one could add all 384 LDR primers simultaneously, and they would sort themselves out. This would allow accurate quantification and enumeration of 768 targets in just 4 LDR reactions.
For 384 Potential Targets. (with Adding UniTaq Primer Sets at Right Angles, and Drying them Down Before Assembly.)
Requires spotting 24× of either 16, 32, or 64 nested PCR primer pairs on the front side of the array.
Prophetic Example 18—Example of PCR Primer Design with Split UniTaq Probe (UniRq) Example of PCR Primer Design with Split UniTaq Probe (UniRq) for FIG. 18: (Tm=64.6) (186 bp Total; 28+28 bp TS DNA)
Notes based on OligoAnalyzer 3.1 Tm calculations:
Internal bold sequences ti & ti′ hairpin at 62.6° C., entire structure is given Tm value of 53.1° C.
Internal italic sequences tj & tj′ hairpin at 59.7° C., entire structure is given Tm value of 53.1° C.
Separate bold sequences ti & ti′ hybridize at 38.6° C.
Separate italic sequences tj & tj′ hybridize at 37.2° C.
Separate double underlined sequences Bi & Bi′ and Bj & Bj′ have Tm of 30.2 and 47.6, respectively
Combining the four hairpin regions gives, results in overall hairpin Tm at 64.6.
Potential primer-dimer PCR product (Tm of probe portion hybridizing to both split complements=54.4)
(Note: Since the primer dimer lacks authentic target sequence TCCGATAGTGA-A-AGCGATAGTAC (SEQ ID NO: 24), hybridization of PCR primers to such a product will not liberate the 3′ block, and thus will not amplify.)
Notes based on OligoAnalyzer 3.1 Tm calculations:
Internal bold sequences ti & ti′ hairpin at 62.6° C., entire structure is given Tm value of 53.1° C.
Internal italic sequences tj & tj′ hairpin at 59.7° C., entire structure is given Tm value of 53.1° C.
Separate bold sequences ti & ti′ hybridize at 38.6° C.
Separate italic sequences tj & tj′ hybridize at 37.2° C.
Separate double underlined sequences Bi & Bi′ and Bj & Bj′ have Tm of 36.4 and 42.7, respectively
Combining the four hairpin regions gives an overall hairpin at 62.6.
Potential primer-dimer PCR product (Tm of probe portion hybridizing to both split complements=51.4)
(Note: Since the primer dimer lacks authentic target sequence TCCGATAGTGA-A-AGCGATAGTAC (SEQ ID NO: 36), hybridization of PCR primers to such a product will not liberate the 3′ block, and thus will not amplify.)
Notes Based on OligoAnalyzer 3.1 Tm Calculations:
Internal bold sequences zi & zi′ hairpin at 64° C.; entire structure is given Tm value of 57.4° C.
Separately, bold sequences zi & zi′ hybridize at 42.9° C.
Separate double underlined sequences Bi & Bi′ and Bj & Bj′ have Tm of 35.1 and 50.3, respectively.
Combining the three hairpin regions results in Tm of 66.6
This example demonstrates how to use a split zip-code design with a probe attached to one of the primers, as in traditional UniTaq. Here the advantage is that the probe oligonucleotide will hybridize to either the upstream LDR primer, or the downstream LDR primer, but will only hybridize to both when the two separate LDR probes are covalently linked and can hybridize to each other. As above, the LDR reaction is performed at 10 nM probe, and the product is diluted 10-fold when going into the UniTaq reaction, meaning the maximum LDR primer concentration is 1 nM, or about 250 to 500-fold lower than the UniTaq probe concentration. Thus, as above, the likelihood of three-way hybridization when two of the probes are at 1 nM, drops to zero. However, when there is LDR product, it gets amplified, increasing the overall concentration of product, and now it is just a single molecule hybridizing to itself (the amplified LDR product containing the attached UniTaq probe).
Prophetic Example 21—Example of LDR Primer Design with Separate Split UniTaq Probe (UniSpTq) Example of LDR Primer Design with Separate Split UniTaq Probe: (Tm=65.2) (150 bp Total; 60 bp TS DNA)
Notes based on OligoAnalyzer 3.1 Tm calculations:
Internal bold sequences zi & zi′ hairpin at 64° C.; entire structure is given Tm value of 56.3° C.
Separately, bold sequences zi & zi′ hybridize at 44.7° C.
Separate double underlined sequences Bi & Bi′ and Bj & Bj′ have Tm of 43.0 and 45.9, respectively.
Combining the three hairpin regions gives a Tm of 65.2.
This example demonstrates how to use a split zip-code design with a separate probe. Here the advantage is that the probe oligonucleotide will hybridize to either the upstream LDR primer, or the downstream LDR primer, but will only hybridize to both when the two separate LDR probes are covalently linked and can hybridize to each other. More importantly, consider that while the average PCR experiment uses a 100 to 500 nM primer concentration, the LDR reactions described herein use a 10 nM primer concentration. The product is diluted 10-fold when going into the UniTaq reaction, meaning the maximum LDR primer concentration is 1 nM, or about 250 to 500-fold lower than the UniTaq probe concentration. Thus, the likelihood of three-way hybridization when two of the probes are at 1 nM, drops to zero. However, when there is LDR product, it gets amplified, increasing the overall concentration of product, and now it is just two molecules hybridizing to each other (the amplified LDR product and the UniTaq probe).
Prophetic Example 22—Example of qLDR Primer Design with Isothermal RNaseH2 Cleavage of Added Universal Probe (UniLDq) Example of qLDR Primer Design with Isothermal RNaseH2 Cleavage of Added Universal Probe (UniLDq; FIG. 22): (Tm=64.8); (145 bp Total; 60 bp TS DNA)
Notes based on OligoAnalyzer 3.1 Tm calculations:
Internal bold sequences ti & ti′ hairpin at 67° C., entire structure is given Tm value of 67.7° C.
Internal italic sequences tj & tj′ hairpin at 63.7° C., entire structure is given Tm value of 67.7° C.
Separate bold sequences ti & ti′ hybridize at 38.6° C.
Separate italic sequences tj & tj′ hybridize at 37.2° C.
Separate double underlined sequences Bi & Bi′ and Bj & Bj′ have Tm of 36.4 and 42.7, respectively.
Combining the 4 double-stranded stem regions gives a Tm value at 64.8.
Prophetic Example 23—qLDR Primer Design with Isothermal RNaseH2 Cleavage of Added Target-Specific Probe (TsLDq) Example of qLDR Primer Design with Isothermal RNaseH2 Cleavage of Added Target-Specific Probe (TsLDq; FIG. 23): (Tm=62) (84 bp Total, Example for B-Raf V600E Mutation)
Notes based on OligoAnalyzer 3.1 Tm calculations:
Combined pieces of upstream & downstream LDR primers ACGGAGAAATCTCG (SEQ ID NO: 66), 14-mer, with Tm of 50.5° C.
Double underlined sequences Bi & Bi′: CGAGTTTCCTTGG (SEQ ID NO: 67) has Tm of 47.8° C.
Combining the 2 double-stranded stem regions gives a Tm value at 62° C.
Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.
Claims
1-54. (canceled)
55. A method for preparing a system for identifying a plurality of nucleic acid molecules in a sample, said method comprising:
- providing the system comprising: (i) an inlet port and (ii) a cartridge defining a space containing: multiple primary reaction chambers fluidically coupled to said inlet port to receive material from said inlet port and produce primary reaction chamber products from the material; a product capture housing enclosing a solid support with a plurality of separate columns of a plurality of product capture subdivisions configured in separate rows and columns, with each separate product capture subdivision comprising an array of a plurality of individual hydrophilic micro-pores or micro-wells, wherein each of said individual hydrophilic micro-pores or micro-wells is separated by hydrophobic surfaces where primary reaction products are further reacted to create array products which are detected in the micro-pores or micro-wells, wherein one or more of the columns of separate product capture subdivisions receive material which has passed through one of said multiple primary reaction chambers; multiple secondary reaction chambers, one or more of which are fluidically coupled to one of said multiple primary reaction chambers to receive material from one of said multiple primary reaction chambers; and multiple mixing chambers each fluidically coupled to one of said multiple secondary reaction chambers to receive material from one of said multiple secondary reaction chambers and to discharge material to said product capture housing so that each column of separate product capture subdivisions is fluidically coupled to one of said multiple mixing chambers to receive material from one of said mixing chambers and
- applying universal tag or capture oligonucleotide primers or probes to the micro-pores or micro-wells of the product capture subdivisions on the solid support within said product capture housing, whereby the universal tag or capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells.
56. The method of claim 55 further comprising:
- filling said multiple primary reaction chambers and/or secondary reaction chambers with primary or secondary reaction oligonucleotide probes or primers each having a first portion comprising a nucleotide sequence complementary to a portion of target nucleic acids in the sample.
57. The method of claim 56, wherein the primary or secondary reaction oligonucleotide probes or primers further comprise a second portion comprising a nucleotide sequence which is the same as or complementary to a portion of a universal tag or capture oligonucleotide primers, retained within the micro-pores or micro-wells.
58. The method of claim 55, wherein each of said product capture subdivisions comprises an array of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage in fluid communication with the second end of the micro-pores, wherein the universal tag or capture oligonucleotide primers or probes are applied to the micro-pores by a method comprising the following steps in the sequence set forth as follows:
- passing the universal tag or capture oligonucleotide primers or probes through the first passage into the micro-pores through their first open ends while hydrophobic liquid is passed through the second passage;
- passing a hydrophobic liquid through the first passage while the hydrophobic liquid is passed through the second passage;
- passing a volatile solvent through the first passage while the hydrophobic liquid is passed through the second passage; and
- passing air through the first passage while heat, a hydrophobic liquid, a volatile solvent, and then air is passed through the second passage.
59. The method of claim 55, wherein each of said product capture subdivisions comprises an array of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage separated from the second end of the micro-pores by a mesh screen covering the second ends, in fluid communication with a second passage, wherein the detection or capture oligonucleotide primers or probes are applied to the micro-pores by a method comprising the following steps in the sequence set forth as follows:
- passing the universal tag or capture oligonucleotide primers or probes through the first passage into the micro-pores through their first open ends;
- passing a hydrophobic liquid through the first passage to expel the universal tag or capture oligonucleotide primers or probes from the first passage;
- passing a hydrophobic liquid through the first passage while a hydrophobic liquid is passed through the second passage;
- passing a volatile solvent through the first passage while a hydrophobic liquid is passed through the second passage; and
- passing air through the first passage while heat, a hydrophobic liquid, a volatile solvent, and then air is passed through the second passage.
60. A process of identifying a plurality of nucleic acid molecules in a sample using a system comprising:
- (i) an inlet port and
- (ii) a cartridge defining a space containing: multiple primary reaction chambers fluidically coupled to said inlet port to receive material from said inlet port and produce primary reaction chamber products from the material and a product capture housing enclosing a solid support with a plurality of separate columns of a plurality of product capture subdivisions configured in separate rows and columns, with each separate product capture subdivision comprising an array of a plurality of individual hydrophilic micro-pores or micro-wells, wherein each of said individual hydrophilic micro-pores or micro-wells is separated by hydrophobic surfaces where primary reaction products are further reacted to create array products which are detected in the micro-pores or micro-wells, wherein one or more of the columns of separate product capture subdivisions receive material which has passed through one of said multiple primary reaction chambers;
- applying universal tag or capture oligonucleotide primers or probes to the micro-pores or micro-wells of the product capture subdivisions on the solid support within said product capture housing, whereby the universal tag or capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells;
- filling said multiple primary reaction chambers with primary reaction chambers with primary reaction oligonucleotide probes or primers each having a first portion comprising a nucleotide sequence complementary to a portion of target nucleic acids in the sample;
- conducting the primary reaction in said system; and
- obtaining the nucleotide sequence of target nucleic acid molecules in the sample following said conducting the primary reaction.
61. The process of claim 60, wherein said conducting the primary reaction comprises:
- providing a sample comprising a plurality of target nucleic acid molecules;
- contacting the sample with a set of primary oligonucleotide primers having a first portion complementary to a portion of the target nucleic acid molecules and a second portion and a polymerase to form a polymerase chain reaction mixture;
- subjecting said polymerase chain reaction mixture to a polymerase chain reaction in the multiple primary reaction chambers to produce a set of amplification products; and
- passing the amplification products to said product capture housing enclosing a solid support with a plurality of separate columns of a plurality of capture subdivisions with each separate product capture subdivision comprising an array of a plurality of individual micro-pores containing immobilized captures probes complementary to the second portion, wherein said obtaining the nucleotide sequence of target nucleic acid molecules in the sample is carried out in said micro-pores.
62. The process of claim 61, wherein the product capture subdivisions comprise an array of a plurality of individual micro-pores each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end.
63. The process of claim 62 further comprising:
- a mesh screen covering the second ends of the micro-pores in said product capture housing.
64. The process of claim 61 further comprising:
- a bead containing said immobilized capture probes placed in the individual micro-pores.
65. The process of claim 61 further comprising:
- removing at least one second portion from said amplification product before said obtaining the nucleotide sequence and after said subjecting said polymerase chain reaction mixture to a polymerase chain reaction.
66. The process of claim 65, wherein said removing is carried out with uracil DNA glycosylases, apurinic/apyrimidinic endonuclease, endonuclease III, endonuclease IV, endonuclease V, alkyladenine DNA glycosylase, formamidopyrimidine DNA glycosylase, or 8-oxyguanine DNA glycosylase, or combinations thereof.
67. The process of claim 60, wherein each of said product capture subdivisions comprises an array of individual micro-pores or micro-wells each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end with a first passage in fluid communication with first end of the micro-pores and a second passage in fluid communication with, and separated from, the second end of the micro-pores by a mesh screen covering the second ends of the micro-pores and wherein said obtaining the nucleotide sequence is carried by a process comprising the following steps in the sequence set forth as follows:
- passing the products of a polymerase chain reaction into said product capture housing through said first passage;
- passing hydrophobic liquid through said first passage, such that the products are distributed into individual micro-wells;
- passing hydrophobic liquid through said first and second passages;
- amplifying said products in a polymerase chain reaction and/or isothermal reaction using the capture oligonucleotide primers under conditions to generate amplification products that are immobilized to the interior surface of the micro-wells;
- passing a volatile solvent through said first passage while passing hydrophobic liquid through said second passage;
- denaturing the products of the polymerase chain reaction and/or isothermal reaction and washing away non-anchored nucleic acid molecules through the first passage while passing hydrophobic liquid through said second passages, such that the products are isolated in individual micro-wells;
- passing hydrophobic liquid with a higher density than water through said first passages while passing volatile solvent, air, and then sequencing reagents through the second passages; and
- carrying out a sequencing reaction in said product capture subdivision.
68. A system for identifying a plurality of nucleic acid molecules in a sample, said system comprising:
- (i) an inlet port;
- (ii) an outlet port; and
- (iii) a cartridge fluidically coupling said inlet port and said outlet port and defining a space containing:
- a product capture housing enclosing a solid support with a plurality of product capture subdivisions configured in separate rows and columns, with each separate product capture subdivision comprising an array of a plurality of individual hydrophilic micro-pores, wherein each of said individual hydrophobic micro-pores is separated by hydrophobic surfaces each having opposed first and second open ends with the first end having a large diameter and the second end having a diameter which is smaller than that of the first end, said product capture housing comprising a plurality of fluid channels to permit material to pass from said inlet port through a column of the product capture subdivisions into contact with the array of micro-pores in those subdivisions, and to said outlet port, wherein the plurality of fluid channels are located above and below the solid support.
69. The system of claim 68 further comprising:
- one or more valves for selectively introducing or removing reagents and/or reactants into or out of said product capture housing through said inlet port or through said outlet port.
70. The system of claim 68 further comprising:
- one or more heating elements in said cartridge proximate to said product capture housing.
71. A method for preparing a system for identifying a plurality of nucleic acid molecules in a sample, said method comprising:
- providing the system of claim 68 and
- applying capture oligonucleotide primers or probes to the micro-pores of the product capture subdivisions on the solid support within said product capture housing, whereby the capture oligonucleotide primers or probes are retained within the micro-pores or micro-wells.
72. A process of identifying a plurality of nucleic acid molecules in a sample using the system prepared by the method of claim 71, wherein, following said applying capture oligonucleotide primers or probes to the micro-pores, said process comprises:
- conducting the reactions in said system and
- detecting the presence of target nucleic acid molecules in the sample in the micro-pores based on said conducting the reactions.
Type: Application
Filed: Feb 14, 2022
Publication Date: Jun 2, 2022
Inventor: Francis BARANY (New York, NY)
Application Number: 17/671,033
